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Abstract 
 
Type 2 diabetes (T2D) is a chronic disease characterised by a range of dysfunctions in 
glycaemic regulation. These dysfunctions are known to include insulin resistance (IR), hyper-
insulin secretion, hypo-insulin secretion and altered hepatic glucose balance, all in the 
course of developing the disease. IR, in particular, is a condition in which the circulating 
insulin is less effective in lowering the glucose levels in blood. Insulin hypersecretion is most 
associated with pre-diabetes, but can sometimes occur in early diabetes in concert with 
sufficient IR. Insulin hyposecretion, on the other hand, is most often present in longer-term 
diabetes and is a result of reduction in β-cell mass. Hence, the ability to accurately monitor 
and diagnose these stages of progression would offer unique insight and clinical 
opportunity. 
 
As an individual progresses towards T2D, the amount of insulin required to deal with the 
glucose loads increases. This outcome is ultimately driven by low insulin sensitivity (SI = IR-1). 
Additionally, T2D is said to have a lower insulin secretion capability, and thus, resulted in 
consistently increase glucose levels in the blood. Thus, more specifically, precisely observing 
and understanding the metabolic disorder as changes in both SI and endogenous insulin 
secretion (UN) may provide further insight into the heterogeneous etiology of type 2 
diabetes, and clinical intervention opportunities.  
 
Although, several test protocols and mathematical modelling strategies have been 
developed to quantify these key aspects of T2D, particularly in SI and UN, the goal of this 
xiv 
 
thesis is to find how to effectively improve the precision and clinical utility of these model-
based assessments when assessing the SI and UN. This thesis focuses on minimising the 
identification error or accurately identify the SI value particularly for individual with 
established T2D. In addition, this thesis also develops and analyses a proportional-derivative 
(PD) control model that may potentially be able to replace the conventional and accepted 
methods for estimating the participant-specific UN profile, which are not precise and thus 
introduce error. 
 
In particular, many modelling strategies use fasting glucose (G0) as basal glucose 
concentration (GB) when assessing the insulin sensitivity. With the assumption of GB = G0, 
most of the model-based SI assessment able to produce a highly correlated of an SI value to 
gold standard euglycaemic hyperinsulinaemic clamp (EIC). However, some of the model-
based like dynamic insulin sensitivity and secretion test (DISST), was developed in a 
relatively healthy, normoglycaemic cohort. Thus, the assumption of GB = G0 might be untrue 
as prior studies have suggested that GB and G0 should be treated differently particularly for 
T2D individuals. Hence, the outcomes of identifying GB potentially provide accurate 
assessment of SI value, in particular, for pre-diabetes individual, are investigated and 
quantified for the first time. 
 
It is understandable that UN plays a leading role in glucose homeostasis. Pathological 
changes in UN can enable early diagnosis of metabolic dysfunction before the emergence of 
type 2 diabetes. A PD control model that defines UN as a function of glucose concentration is 
proposed and analysed to provide further insight and modelling capability for this 
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prediabetic state. In addition, it offers the ability to add precision to estimating SI and 
additional diagnostics around UN. 
 
Thus, finally, the proposed PD UN model is further analysed to provide more information in 
determining each participant’s glycemic condition. The characterised gains of derivative 
control, 𝜙𝐷 and proportional control, 𝜙𝑃 are used in identifying and discriminating the UN 
profile for each metabolic state. Hence, the outcome will potentially improve the overall 
identification of UN profile. 
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Chapter 1. Introduction 
 
Diabetes has gone from rarity to global epidemic. Global estimations of diabetes prevalence 
by King et. al. estimate that there will be a total of 300 million adults with diabetes in 2025 
(King et al. 1998). The World Health Organization (WHO) estimates an increase of more than 
110%, from 171 million in 2000 to 366 million in 2030, of diabetes case worldwide (Wild et 
al. 2004). The International Diabetes Federation (IDF) estimates that the total number of 
people living with diabetes will rise about 55% from 382 million in 2013 to 592 million in 
2035 (IDF 2013). While these estimates vary wildly, they share common themes of 
exponential growth and large number of people with diabetes. 
 
Diabetes continues to increase in prevalence and significance due to developments in 
economics and urbanization that lead to sedentary lifestyles changes leading to reduced 
physical activity and increasing obesity (Whiting et al. 2011). Diabetes is characterised by 
high levels of insulin resistance and insulin secretory dysfunction that affect glucose uptake 
and utilization by most cells of the human body. Thus, a combination of resistance to insulin 
action and an increasingly inadequate compensatory insulin secretory response results in 
changing the metabolic state of an individual a healthy state, through pre-diabetes and early 
onset type 2 diabetes to manifest diabetes (Ferrannini 1997; WHO 2006). In particular, an 
absolute deficiency of insulin secretion occurs in manifest diabetes (ADA 2014). Hence, 
understanding the underlying metabolic disorder in the pathogenesis of diabetes could 
provide valuable information to instigate therapies to mitigate or delay the onset of the 
disease.  
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This chapter reviews and discusses the physiological characteristics of glucose and insulin 
that are associated with insulin resistance and the pathogenesis of type 2 diabetes. 
 
1.1 Glucose 
 
Glucose is a simple sugar or monosaccharide that consists of three elements: carbon, 
hydrogen and oxygen. Glucose is the most important carbohydrate and is used by the body 
as the main source of energy. During the conversion of glucose to pyruvate via glycolisis, 
energy is released for use in the cells (Guyton & Hall 2006). Hence, adequate glucose is 
essential in providing energy to maintain cellular function and thus, the body. 
 
Figure 1.1 illustrates the level of glucose in the blood stream in a simulated healthy 
individual. Immediately after a meal, the digestive system breaks down the carbohydrate in 
food into glucose. The glucose produced is absorbed into the blood stream and results in 
sharp increase in blood glucose level. A healthy individual has a blood glucose level of 72 - 
90 mg·dL-1 (4 - 5 mmol·L-1) before a meal. However, the blood glucose level of most healthy 
individuals will increase above 140 mg·dL-1 (7.78 mmol·L-1) after a meal containing large 
amounts of carbohydrates (Guyton & Hall 2006). In response to the increased blood glucose 
level, pancreatic β-cells secrete a significant amount of insulin to lower the blood glucose 
level back to a safe level.  
 
Glucose is transported around the body passively via the blood stream. Insulin is required to 
mediate glucose uptake into cells, thus removing it from the blood, particularly in the liver, 
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muscles and adipose tissue. Glucose can also be directly taken up by cells itself in the brain 
and central nervous system without the need of insulin. 
 
 
Figure 1.1: Schematic illustration of the effect of blood glucose level after meal. 
 
Although, glucose is used by the cells to produce energy, excess glucose can be stored in the 
liver and muscles, primarily as glycogen, for future use. However, the body’s ability to store 
glycogen is limited. Hence, further excess glucose is then stored in adipose tissue as fat.  
 
Naturally, the body constantly regulates the blood glucose level as a part of metabolic 
homeostasis. A healthy fasting blood glucose level is in the range of 4 – 5 mmol·L-1. 
However, if this glucose balancing system is disrupted, it can lead to hyperglycemia, where 
the blood glucose level is elevated above safe levels (≥ 200 mg·dL-1,   11.1 mmol·L-1) (ADA 
2014; WHO 2006). If left untreated, hyperglycemia can lead to the emergence of T2D and 
significant complications (Duckworth 2001; Laakso 1999a,b). On the other hand, if blood 
glucose levels fall too low, into the range of 20 – 50 mg·dL-1 (1.11 – 2.78 mmol·L-1), 
hypoglycaemia occurs (Guyton & Hall 2006), which carries its own significant risk (Cryer 
1997; Cryer & Polonsky 2008; McCrimmon & Frier 1994; Wilson 1983) and thus adds risk to 
treating hyperglycemia with insulin.  
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An individual is defined as having impaired fasting glucose (IFG) when the value of fasting 
plasma glucose is in the range of 100 mg·dL-1 (5.6 mmol·L-1) to 125 mg·dL-1 (6.9 mmol·L-1), or 
impaired glucose tolerance (IGT) when the plasma glucose value in the range of 140 mg·dL-1 
(7.8 mmol·L-1) to 199 mg·dL-1 (11 mmol·L-1) at the 2-hour mark of an oral glucose tolerance 
test (OGTT) (ADA 2014). These IFG and IGT individuals have been referred to as having a 
pre-diabetes state, indicating a high risk of further development of diabetes (ADA 2014; 
Shaw et al. 1999; Tuomilehto et al. 2001; Vendrame & Gottlieb 2004). Maintaining a 
balanced glucose level in the blood is crucial for health. Failing to continually control blood 
glucose levels leads to the development of metabolic disorders, particularly diabetes, all of 
which have significant complications that can reduce quality and length of life. 
 
1.2 Insulin 
 
One of the primary hormones produced by pancreatic β-cells of the islets of Langerhans is 
insulin (Guyton & Hall 2006). The insulin hormone is composed of two polypeptide chains, A 
(21 amino acids) and B (30 amino acids) chains. These two amino acids are connected by 
disulfide bonds (Chevenne et al. 1999).  
 
Insulin plays the primary significant role in maintaining glucose homeostasis. The β-cells, 
representing 60% of all the cells of the islets of Langerhans, secrete insulin in response to 
elevated glucose levels in the blood stream. These insulin secretions enable glucose to be 
absorbed by muscle and adipose tissue cells, regulate storage and release of glucose in the 
liver, and promote fat synthesis and storage (Guyton & Hall 2006; Jefferson et al. 2001). 
Hence, it dominates the glucose removal portion of human metabolic regulation. 
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Figure 1.2 illustrates the important role played by insulin in glucose uptake. Once released 
into the blood stream, insulin is then distributed to interstitial fluid. There, it binds to its 
receptor of muscle and adipose tissue cell outer membranes. This action, in turn, activates 
an intercellular reaction that include translocation of glucose transporter proteins from 
intracellular vesicles to the plasma membrane (Holman & Kasuga 1997; Myers & White 
1996), which then results in influx of glucose (Jefferson et al. 2001).  
 
 
Figure 1.2: Effect of insulin on glucose uptake and metabolism. Adapted from 
http://biology-pictures.blogspot.co.nz/. 
 
Once, glucose enters the cell, it undergoes energy-releasing glycolysis process that. In the 
case of energy abundance, insulin also plays a critical role in storing the excess energy 
mainly in the liver and muscles by converting the glucose into glycogen through 
glycogenesis. Moreover, it also promotes the synthesis of fatty acids through lipogenesis, 
where the energy is stored in adipose tissue as fats (Guyton & Hall 2006).   
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Initially, the β-cells secrete insulin into the portal vein and it travels through the liver to the 
heart before entering the blood circulation. From 60 – 80% of endogenous insulin secretion 
is extracted during this first pass extraction by the liver after being released (Cobelli & Pacini 
1988; Ferrannini & Cobelli 1987; Meier et al. 2005; Toffolo et al. 2006). Later, insulin is also 
cleared by the kidneys, as well as through cellular degradation after mediating glucose 
uptake (Guyton & Hall 2006; Jefferson et al. 2001). Hence, there are multiple clearance 
paths. 
 
In general, the secretion of insulin by the pancreatic β-cells is bi-phasic in healthy individuals 
(Guyton & Hall 2006; Jefferson et al. 2001). The strong spike of first phase secretion is 
released from stored and pre-produced insulin immediately after a sudden increase in 
glucose level within a short period of time. Later, a prolonged second phase secretion is 
more slowly and gradually released to eventually bring glucose levels back to normal. 
Importantly, the healthy pancreas secretes the right amount of insulin in response to the 
appearance of glucose in the blood stream. Failure to produce enough insulin to clear the 
excess glucose leads to elevated glucose levels in the blood and ultimately to prolonged 
hyperglycemia and T2D. 
 
1.3 Pathogenesis of Type 2 diabetes mellitus (T2DM) 
 
Diabetes mellitus is a chronic disease characterized by prolonged or uninterrupted elevated 
blood glucose levels (hyperglycemia) resulting from defects in insulin secretion, insulin 
action, or both (ADA 2014). Naturally, glucose homeostasis is achieved when the level of 
glucose is consistently controlled to a normal basal level of approximately 4 – 5 mmol·L-1. 
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Regulation is accomplished via glucose uptake by the cells via insulin mediated uptake. 
However, as the body’s ability to regulate glucose levels in blood deteriorates, the glucose 
stays in the blood stream until it is cleared, more slowly, through renal clearance of the 
kidneys (Arleth et al. 2000). This abnormal condition occurs in established diabetes and 
results in prolonged elevated blood glucose concentrations.  
 
There are two major types of diabetes, Type 1 and Type 2 (Guyton & Hall 2006). Figure 1.3 
illustrates the etiopathogenesis of these two types. In general, Type 1 diabetes (T1D) results 
from the body’s failure or inability to produce insulin. The etiology of T1D is characterised by 
the destruction of the pancreatic β-cells caused by an auto-immune disorder or as a result 
of the action of genetic markers (ADA 2014; Bluestone et al. 2010). Individuals with T1D 
need to have exogenous insulin to maintain a safe level of glucose in the blood stream.   
 
T2D results from the body’s inability to produce enough insulin. Prior studies and definitions 
have characterized T2D by fasting hyperglycemia and an excessive rise in the plasma glucose 
concentration above baseline following glucose or meal ingestion (DeFronzo et al. 1983) 
resulting from impaired insulin utilization (insulin resistance) coupled with the body’s 
inability to compensate with insulin production (insulin deficiency). Hence, there is a 
fundamental difference in the two forms of diabetes. 
 
Theoretically, it can be said that type 2 diabetes is related to the development of IR and 
impaired β-cells. Over time, T2D is developed due to consistent and excessive insulin 
resistance leading to increase requirements for insulin production that, if not halted, 
eventually leads to loss of β-cell function and diminished secretion. Thus, loss of β-cells 
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eventually results in a total loss of insulin secretion. Hence, the glucose level in the blood 
increases, increasingly without restraint. 
 
 
Figure 1.3: Illustration of the pathophysiological differences between normal, type 1 and 
type 2 diabetes. Adapted from endocrineweb.com/endocrinology/overview-pancreas. 
 
As a result, it is generally agreed that insulin resistance is the predominant driver of the 
pathogenesis of T2D (Docherty 2011). A study has reported that up to 10 years ahead of a 
formal diagnosis of type 2 diabetes, those who developed the disease had 60% higher mean 
IR than those that did not (Martin et al. 1992). It is also found that amongst obese 
individuals, IR is the strongest predictor of subsequent type 2 diabetes and cardiovascular 
disease risk (McLaughlin et al. 2007). Figure 1.5 shows a clear relationship between insulin 
production, insulin sensitivity and glucose concentration in blood stream. The nature of 
insulin production increases and subsequently reaches a maximised plateau before 
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declining, as illustrated in Figure 1.4. This behaviour is known as Starlings curve of the 
pancreas (Clark et al. 2001; Gastaldelli et al. 2004). A similar curve was also presented in 
Ferrannini et. al. (Ferrannini 1997). 
 
Figure 1.4: A generalisation of the inter-relationships between insulin production, insulin 
sensitivity and glucose concentration during the pathogenesis of type 2 diabetes (T2D). Note 
that NGT and IGT are normal glucose tolerance and impaired glucose tolerance, 
respectively. Adapted from (Docherty 2011). 
 
As an individual moves from normal glucose tolerance (NGT) to IGT, the glucose 
concentration often remains the same. However, the SI value decreases as IR increases, as 
defined. This decrease results in higher demands on insulin production to stabilize blood 
glucose levels. As a result, this physiological change often goes unnoticed for a long time. 
Thus, the disease can be well established long before diagnosis when insulin production 
becomes significantly impaired and blood glucose levels rise. Hence, early identification of 
insulin resistance or sensitivity, as well as insulin production, could potentially ameliorate 
the worst long term symptoms of the disease if appropriate intervention is taken. 
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1.4 Preface 
 
The main objective of this thesis is to better understand the identification of SI and β-cell 
function through the secretion of endogenous insulin. This thesis focuses on two parts: 1) 
accurately assessing SI value particularly for individuals with established T2D from the 
perspective of model-based SI assessment; and 2) identifying a smoother physiologically UN 
profile based on a development of PD control model. A brief overview of the thesis includes: 
 
Chapter 1 discusses the physiological characteristics of glucose and insulin that are associate 
with IR and the pathogenesis of T2D. 
 
Chapter 2 reviews current and established model-based SI assessments. 
 
Chapter 3 introduces a 3-parameter modelling approach for SI assessment. The approach is 
compared to a previous 2-parameter identification for individuals with established T2D. 
 
Chapter 4 validates the importance of introducing GB as a variable in a 3-parameter 
identification approach using DISST model. 
 
Chapter 5 underlines the impact of identifying GB as a variable towards assessing the SI 
value. 
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Chapter 6 explores a different modelling approach of identifying the UN profile through the 
development of PD UN model as opposed to the typical approach of deconvolution of C-
peptide measurements. 
 
Chapter 7 presents a PD model that defines UN as a function of changes in glucose 
excursion.  
 
Chapter 8 reflects how the information gathered from PD UN model can be used in 
discriminating the condition state of an individual.  
 
Chapter 9 summarises and concludes the outcomes of this thesis. 
 
Chapter 10 defines possible future work for this research. 
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Chapter 2. Review of model-based insulin sensitivity 
(SI) tests 
 
This thesis revolves around model-based assessment of insulin sensitivity and insulin 
secretion in the clinical evaluation of the etiology and diagnosis of diabetes. This chapter 
provides an overview of current model-based methods for assessing insulin sensitivity (SI), 
which is, as noted, an important metabolic marker of risk for type 2 diabetes. 
 
2.1 Introduction 
 
T2D is a metabolic disease that affects the body’s ability to regulate blood glucose 
concentrations (DeFronzo & Ferrannini 1991; Ferrannini 1997; Martin et al. 1992). Studies 
show that T2D is characterized by fasting and postprandial hyperglycaemia (DeFronzo et al. 
1983; Firth et al. 1986; Kirkman et al. 2006; Rizza 2010) and causes complications 
comorbidities with significant personal, social and economic cost (Bonow & Gheorghiade 
2004; Gakidou et al. 2011; King 1999; Lam & LeRoith 2012; Santaguida et al. 2005). 
Although, this hyperglycaemia is attributed to a combination of impaired insulin utilization 
(insulin resistance) and a limited ability to compensate with insulin production (net insulin 
deficiency), many investigations found that SI (SI = IR-1) is a key causative and diagnostic 
factor in T2D (DeFronzo & Ferrannini 1991; Ferrannini 1997; Harris et al. 2003; Martin et al. 
1992) and is also associated as a major risk factor for cardiovascular disease (Hanley et al. 
2005; McLaughlin et al. 2007; Santaguida et al. 2005; Zimmet et al. 1999). Thus, a practical 
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test that able to accurately identify SI would be clinically advantageous as a diagnostic and 
to better understand the physiological changes in T2D.  
 
Many already developed tests measure SI as the efficiency in the use of insulin to reduce 
blood glucose (Ferrannini & Mari 1998; Pacini & Mari 2003). Each test employs a different 
clinical method, and thus results in a different level of accuracy or resolution. Hence, the 
researcher or clinician has to choose the best test in terms of intensity, cost, accuracy and 
physiological relevance. Therefore, a high resolution, simple, repeatable clinical measure of  
insulin  sensitivity  would  have clinical  and  research  benefits for diagnosis, research, and  
evaluating  the  impact  of interventions (ADA 1998). 
 
The aim of this chapter is to provide an overview on the most frequently used insulin 
sensitivity tests and, in particular, model-based SI assessments. However, the vast majority 
of these tests and models have  been  extensively  reviewed  and discusses by  Lotz (Lotz 
2007), Docherty (Docherty 2011) and Jamaludin (Jamaludin 2013). Hence, the focus here, in 
this chapter, is to give a summary of these tests in terms of diagnostic accuracy, as well as 
clinical burden and intensity of assessing the insulin sensitivity and secretion. 
 
2.2 Overview of insulin sensitivity test 
2.2.1 Euglycaemic hyperinsulinaemic clamp (EIC) 
 
The EIC is regarded as the gold-standard for investigating and quantifying insulin resistance 
or insulin sensitivity (Ferrannini & Mari 1998; Pacini & Mari 2003). It measures the amount 
of glucose necessary to compensate for a hyper-physiologically increased insulin level. First 
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introduced in 1979 (Defronzo et al. 1979), this test infuses insulin at a constant rate and 
glucose at a variable rate to “clamp” the plasma glucose concentration at a normal fasting 
concentration, typically around 4.6 – 5.0 mmol·L-1 (McAuley et al. 2001).  
 
The EIC defines an insulin sensitivity index (ISI) as the mean glucose infusion rate is divided 
by the mean insulin concentration. Both variables are measured at a steady state level at 
the end of the test. It has good repeatability (Defronzo et al. 1979; Mari et al. 2001; 
Monzillo & Hamdy 2003). However, it is very difficult to perform, time consuming, and 
increasingly avoided even by clinical researchers (Ferrannini & Mari 1998; Radziuk 2000). In 
addition, the test needs a total of 180 to 300 minutes to complete, with consistent 
attendance by highly trained medical personnel, making it too intensive for subjects and 
clinicians. 
  
Although the EIC test is the gold standard reference for insulin sensitivity value, it does not 
provide an evaluation of a participant’s insulin production at the same time. A second EIC 
test using a sustained hyper-physiological glucose concentration, instead of hyper-
insulinaemia, is performed to estimate the insulin production. Thus, insulin production and 
sensitivity cannot be identified concurrently with the EIC test, and neither is accurately 
estimated at the physiological levels or actions. 
 
2.2.2 Intravenous glucose tolerance test (IVGTT) 
 
The IVGTT is the most well-used and common dynamic insulin sensitivity test protocol. This 
test protocol assesses glucose tolerance through an intravenous injection of glucose. A 
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series of blood samples are taken, and 20 or more samples are then assayed for glucose and 
insulin concentration, and, sometimes, connecting peptide (C-peptide) concentration, as 
well. Since the SI value cannot be identified directly from the data, a non-linear least-square 
parameter identification approach, typically using the minimal-model (MM) of glucose-
insulin dynamics is used to analyse the data (Bergman et al. 1985; Bergman et al. 1979b; 
Bergman et al. 1981; Boston et al. 2003; Caumo et al. 1999).  
 
The minimal model identifies two metabolic parameters, insulin sensitivity (SI
MM) and 
glucose effectiveness (SG
MM). SI
MM defines the sensitivity of insulin to mediate glucose 
uptake and inhibit liver glucose production (Bergman 1989; Bergman et al. 1985). SG
MM, on 
the other hand, quantifies the ability of glucose to decay from plasma at constant basal 
insulin (Ader et al. 1985; Best et al. 1996). In addition, the minimal model has been used 
with other models to identify metrics of first and second phase insulin secretion (Toffolo et 
al. 1980).  
  
The insulin sensitivity metrics from the IVGTT have been well-validated against the EIC 
(Beard et al. 1986; Bergman et al. 1987; Saad et al. 1994). However, some studies have 
shown significant difference to the EIC with R = 0.44 – 0.85 (Donner et al. 1985; Foley et al. 
1985; Galvin et al. 1992). Furthermore, the IVGTT is also known to produce ambiguous 
insulin sensitivity values and erratic correlations with the EIC (Bonora et al. 1989; Ferrannini 
& Mari 1998). Although, the IVGTT and minimal model are less clinically intense than the 
EIC, it remains a research-only application as the test is still impractical for use in wider 
clinical setting due to its length, intensity and complexity of parameter identification 
approach. 
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2.2.3 Oral glucose tolerance test (OGTT) 
 
The OGTT is a simple test that involves oral consumption of a drink containing a pre-defined 
glucose content. A standard dose of glucose, often 75g glucose in 250 mL of flavoured 
water, is ingested by mouth and blood glucose levels are checked one and/ or two hours 
later. The OGTT is used to diagnose patients of pre-diabetes, type 1 or type 2 diabetes (ADA 
2014). The two most common protocols are the 75g 2-hour trial and the 50g 1-hour trial.  
 
The OGTT by itself, does not calculate insulin sensitivity directly and insulin production 
characteristics are not frequently measured or estimated. Its simplicity and accurate 
portrayal of the ability to dispose of glucose have made it the most common clinical 
diagnostic of diabetes (ADA 2014). In particular, the OGTT only measures the body’s ability 
to remove a glucose load throughout the 1 or 2-hour trial, but provides no measure of 
secretion. Instead, it yields the net combination of SI and secretion seen as glucose removal.  
 
A series of mathematical equations have been suggested to be applied, together with the 
OGTT, to assess the insulin sensitivity (Cederholm & Wibell 1990; Gutt et al. 2000; Matsuda 
& DeFronzo 1999; Piche et al. 2007; Stumvoll et al. 2000). The OGTT is rarely used to assess 
SI in clinical investigation. It is instead very well used as an accepted method for the 
diagnosis of diabetes (ADA 2014; WHO 2006). 
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2.2.4 Homeostasis model assessment (HOMA) 
 
HOMA identifies insulin sensitivity and an index of β-cell function based on measured 
plasma glucose and insulin in a fasting state using a very simple physiological glucose-insulin 
model (Levy et al. 1998; Matthews et al. 1985; Turner et al. 1979). HOMA has been 
validated against the EIC. As this method solely depends on the precision of the fasting 
glucose and insulin measurements, a small error may affect the overall calculation of both 
indices of SI and β-cell function (Pacini & Mari 2003). Hence, the correlation between the 
EIC and HOMA varies between R = 0.22 and R = 0.93 (Bonora et al. 2000; Lorenzo et al. 
2010; Mari et al. 2001; Mather et al. 2001; Matthews et al. 1985; Pacini & Mari 2003; Piche 
et al. 2007), with most having on the poor side.  
 
2.2.5 Dynamic insulin sensitivity and secretion test (DISST) 
 
The DISST was designed to obviate the limitations of other tests. It provides quantitative 
measures of insulin sensitivity and insulin secretion. It is a dynamic test with a physiological 
model-based assessment, similar to the insulin modified IVGTT (IM-IVGTT).  The DISST was 
developed to be an accurate IVGTT alternative that enables a shorter test duration, more 
physiological dosing, less frequent sampling, and higher robustness, all with a lower total 
cost of clinical testing (Lotz 2007; Lotz et al. 2010; Lotz et al. 2008).  
 
The DISST uses a low dose of intravenous glucose bolus of 5 – 20 g and is followed by a low 
dose of intravenous insulin bolus of 0.5 – 2 U. Blood samples are measured and assayed for 
glucose, insulin and C-peptide concentration. The DISST identifies the participant-specific SI 
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and also UN through a developed pharmaco-kinetic and pharmaco-dynamic model that 
represent the pathways and interactions between insulin, C-peptide and glucose in the 
human body. 
 
The DISST produces a highly correlated metric of insulin sensitivity to the EIC test through 
in-silico study (R = 0.99) (Lotz et al. 2008). In-vivo studies also yielded a high correlation (R = 
0.82) (McAuley et al. 2011). In addition, the DISST was able to identify participant-specific 
UN profiles through deconvolution of measured C-peptide. As C-peptide is equimolarly 
secreted together with insulin from pancreatic β-cells (Rubenstein et al. 1969), the 
deconvolution method is considered to be effective in indentifying UN profiles (Van Cauter 
et al. 1992). Thus, the DISST is a unique test that can quantify both insulin sensitivity and 
secretion at the same time with low cost but high robustness. 
 
The DISST was further developed by Docherty (Docherty 2011), who eliminated the need for 
insulin and C-peptide assays via an iterative parameter identification method. The quick 
dynamic sensitivity test (DISTq) reduces the clinical intensity and assay cost of the DISST and 
correlated well to the fully sampled DISST in an in-silico Monte-Carlo analysis with R=0.89 
(Docherty et al. 2009). With the low cost and high accuracy of the DISTq, it would be able to 
screen more patients for type 2 diabetes risk (Docherty et al. 2011b). 
 
2.3 Summary 
 
Figure 2.1 shows the relationship between accuracy and intensity of different SI tests. The 
EIC is regarded as the gold standard in assessing SI. However, the EIC test cannot 
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concurrently identify both insulin production and insulin sensitivity, both of which are 
required for accurate diagnosis and understanding of the etiology of diabetes. A second 
clamp protocol is needed to assess UN. Hence, it is only limited to research setting, as it is 
too complex, intense and costly for wider clinical application. 
 
The IVGTT with a minimal model analysis is suggested as a valid alternative to the EIC and is 
widely used by researchers. However, the IVGTT test has not achieved wide acceptance in a 
clinical application given that they are also very complex and time consuming. Additionally, 
relying on the minimal model in analysing and assessing SI, often leads to issues, particularly 
in over-parameterisation that causes the inability to distinguish between insulin and non-
insulin mediated glucose disposal (Docherty et al. 2011a; McDonald et al. 2000; Pillonetto et 
al. 2002). Hence, the test is known to produce inconsistent SI values and unpredictable 
correlation to the EIC particularly for individual with higher insulin resistance (Docherty et 
al. 2011a; Pillonetto et al. 2003; Quon et al. 1994).  
 
The OGTT and HOMA are cheaper and simpler compared to the IVGTT and EIC (Figure 2.1). 
A mathematical model is needed to analyse data obtained from the OGTT to identify an SI 
value. However, the OGTT is not often used in applications that require accurate assessment 
of SI. However, the OGTT is widely accepted and used as a method to diagnose type 2 
diabetes. 
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Figure 2.1: Comparison of different SI tests based on the test’s intensity and accuracy in 
terms of repeatability (CV in %). The clinical target area is added for a better clinical test. 
Adapted from (Jamaludin 2013; Lotz 2007). 
  
HOMA, on the other hand, identifies SI values based on fasting glucose and insulin values. 
However, with only one sample required of both glucose and insulin concentration, it does 
not fully represent the insulin-glucose dynamics. Thus, HOMA is used only in research that 
requires a simple, SI surrogate. 
 
The DISST is a dynamic model-based test, similar to the IM-IVGTT. The DISST was developed 
to capture high resolution estimates of SI and also the UN profile. With high correlation to 
the gold standard EIC with R = 0.82 in in-vivo, the DISST insulin sensitivity is a more 
representative measure than other insulin sensitivity metrics due to its physiological model 
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of pharmaco-kinetic and pharmaco-dynamic of glucose, insulin and C-peptide 
measurements. It also delivers a well-accepted UN secretion profile that others do not. 
 
Although the DISST seems to be the best protocol for assessing SI and UN based on higher 
repeatability and lower intensity (Figure 2.1), there remains a scope better at diagnosis by 
improving the DISST model. The DISST, like any other model-based SI assessment, uses the 
assumption that basal glucose level is equal to the fasting glucose level when assessing 
insulin sensitivity. However, this assumption is untested and may be untrue for individuals 
with established T2D. Originally, the DISST identifies SI together with a glucose distribution 
volume (VG) in a 2 parameter approach employing the iterative integral method (IIM). 
However, if basal glucose is considered as a variable, a 3 parameter approach is needed, 
where basal glucose is identified together with the SI and VG value. Hence, SI can be 
potentially assessed with better accuracy in this case, particularly for T2D individuals.  
 
In addition, the DISST identifies the participant-specific UN profile based on deconvolution of 
C-peptide measurement. Although it remains to be the best method in identifying 
endogenous insulin, due to the fact that C-peptide and insulin are co-secreted from β-cells, 
these C-peptide measurements are relatively sparse. Hence, while diagnostically effective, 
there is room for improvement and to reduce sampling and thus cost, which is the focus of 
this research. 
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Chapter 3. 3-parameter identification of model-based 
insulin sensitivity assessment 
 
This chapter discusses an adaptation to enable identification of 3 parameters, comprising 
GB, SI and VG, when assessing SI value for individuals particularly with established T2D. 
 
3.1 Introduction 
 
The pathogenesis of T2D is well known, and is characterized by IR and β-cell dysfunction 
(Kahn 2003). β-cell dysfunction is associated with reduced and inconsistent endogenous 
insulin production, while IR as a condition refers to a state in which the body becomes less 
effective or unable to use secreted endogenous insulin for lowering blood glucose. An 
individual can have IR with, or without, β-cell dysfunction and reduced insulin secretion. 
These conditions contribute to major metabolic disorders, such as glucose intolerance or 
hyperglycemia, and, if left untreated, ultimately lead to the emergence of T2D.  
 
In particular, IR is a strong early predictor of subsequent T2D, up to 10 years in advance 
(DeFronzo & Ferrannini 1991; Ferrannini 1997; Harris et al. 2003; Martin et al. 1992). It is 
also associated with increased cardiovascular disease risk (Hanley et al. 2005; McLaughlin et 
al. 2007; Zimmet et al. 1999) as part of an overall syndrome of conditions that can emerge. 
Early identification of IR would thus benefit diagnosis and offer the opportunity to reduce 
subsequent risk and its social and economic impact. 
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The ability to quantify SI and UN is essential to improving the understanding of the complex 
physiology underlying type 2 diabetes. The first is associated with IR, while the second is 
associated with the ability to endogenously secrete insulin to reduce glucose level. Thus, it is 
necessary to assess both to enable complete diagnosis. 
 
Throughout the years, many experimental tests have been designed to quantitatively assess 
SI and UN (Bergman et al. 1985; Hovorka & Jones 1994). Mathematical models of glycaemic 
dynamics, in particular, have been coupled with clinical data to identify these 2 key aspects 
in the pathogenesis of type 2 diabetes. However, none have yet been accepted as a clinical 
standard, and are primarily used as research tools. 
 
SI is defined as the ability of insulin (exogenous or endogenous) to lower blood glucose 
concentration by stimulating glucose uptake and suppressing its glucose production (Pacini 
& Mari 2003). The EIC is regarded as the gold standard method for identifying SI (Ferrannini 
& Mari 1998; Pacini & Mari 2003), due to its good accuracy and high repeatability (Defronzo 
et al. 1979; Monzillo & Hamdy 2003). The EIC measures SI through the amount of glucose 
necessary to compensate for a hyper-physiologically increased insulin level while 
maintaining a normal, fasting glucose concentration of about 5 mmol·L-1 (Pacini & Mari 
2003).  
 
However, the EIC is increasingly avoided by clinical researches due to its experimental 
complexity, the need for clinical expertise in administering the test, and its time consuming 
design (Ferrannini & Mari 1998; Radziuk 2000). Thus, the IVGTT with minimal model 
assessment was proposed as a potential way to mitigate the clinical intensity of the EIC 
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(Pacini & Bergman 1986). However, the IVGTT is known to produce ambiguous insulin 
sensitivity values and erratic correlations with the EIC (Bonora et al. 1989; Ferrannini & Mari 
1998). This difficulty is particularly true for those with low SI (higher IR) (Pillonetto et al. 
2002; Quon et al. 1994), which is, paradoxically, the target population requiring the most 
accuracy in an SI test. It is also costly and clinically intensive due to the frequent, typically 1-
3 min, sampling. 
 
The DISST is a low intensity test that incorporates a clinical protocol similar to the IM-IVGTT 
(Bergman et al. 1979b; Ward et al. 2001). The DISST data modelling and data fitting 
methods were customized to the clinical protocol to allow a robust measurement of SI that 
avoids the problems encountered with FS-IVGTT assessment in insulin resistant patients 
(Caumo et al. 1999; Cobelli et al. 1986; Docherty et al. ; Krudys et al. 2006). The DISST also 
compares very favourably with EIC in assessing SI with strong correlation of R = 0.82, and 
produced highly repeatable SI and UN metrics (Lotz 2007; Lotz et al. 2010; Lotz et al. 2008; 
McAuley et al. 2011). In addition, it provides UN and SI resolution where the supra-
physiological EIC does not (Lotz 2007; McAuley et al. 2011).   
 
The pharmacokinetics and pharmacodynamics of the DISST model relates the rate of 
glucose decay to the concentration of insulin available in the interstitium to provide a metric 
of SI (Lotz 2007; Lotz et al. 2010). Like all other model-based assessments of SI (Bergman et 
al. 1979b; Bergman et al. 1981; Bergman et al. 1987; Boston et al. 2003; Caumo et al. 1999), 
the DISST model-based approach uses the participant’s measured G0 as their modelled GB so 
that G0 = GB. Hence, SI is identified together with VG in a 2-parameter identification 
approach.    
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Although, the DISST model, with the assumption of G0 = GB, produces an SI value that is 
highly correlated to the EIC value. However, the model was developed in a relatively 
healthy, normoglycemic cohort (Lotz ; Lotz et al. 2010). Understandably, G0 is defined as a 
glucose concentration taken early in the morning after an overnight fast of 8 hours or more. 
While, GB, on the other hand, is defined as the stable overnight glucose concentration 
(Holman & Turner 1981). Hence, the assumption of G0 = GB might be untrue for some cases, 
particularly those involving low SI value. More specifically, prior studies show that G0 levels 
and insulin concentrations are slightly higher in the morning than their overnight “basal” 
levels, especially for participants with diabetes (Holman & Turner 1977,1978,1979,1981).  
 
In addition, the evidence suggests that GB and G0 should be treated as separate entities for 
individuals with established diabetes as the levels are determined by relative insufficiencies 
in SI, UN and rates of gluconeogenesis (Cahill 1971; Cahill et al. 1959; Steele et al. 1968). 
Therefore, identifying GB as a variable may provide more precise information particularly 
when assessing SI value especially for individuals with T2D. Hence, a new 3-parameter 
identification approach is developed in this chapter, where GB is identified in concert with SI 
and VG. 
 
3.2 DISST Model 
 
The DISST provides quantitative measures of both SI and UN (Lotz et al. 2010; McAuley et al. 
2011; McAuley et al. 2007).  The DISST is similar to the insulin modified IVGTT, which 
typically uses an alternative modelling approach that requires a higher intensity test. The 
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DISST model describes the UN secretion profile from the deconvolution of C-peptide 
concentration (Van Cauter et al. 1992):  
  
C-peptide Pharmaco-kinetic Model 
?̇? = −(𝑘1 + 𝑘3)𝐶 + 𝑘2𝑌 +
𝑈𝑁
𝑉𝑝
 (3.1) 
?̇? = −𝑘2𝑌 + 𝑘1𝐶 (3.2) 
 
The insulin kinetics are described (Lotz et al. 2010): 
Insulin Pharmaco-kinetic Model 
𝐼̇ = −𝑛𝑘𝐼 − 𝑛𝐿
𝐼
1 + 𝛼𝐼𝐼
−
𝑛𝐼
𝑉𝑝
(𝐼 − 𝑄) +
𝑈𝑒𝑥
𝑉𝑝
+ (1 − 𝑥𝐿)
𝑈𝑁
𝑉𝑝
 (3.3) 
?̇? = −(𝑛𝐶 +
𝑛𝐼
𝑉𝑄
)𝑄 +
𝑛𝐼
𝑉𝑄
𝐼 (3.4) 
 
Finally, SI is identified from a glucose insulin pharmacodynamic (PD) model (Chase et al. 
2005): 
Glucose-Insulin Pharmaco-dynamic Model 
?̇? = −𝑝𝑔𝑢(𝐺 − 𝐺𝐵) − 𝑆𝐼(𝐺𝑄 − 𝐺𝐵𝑄𝐵) +
𝑃𝑡
𝑉𝐺
 (3.5) 
 
All values for Equations (3.1) – (3.5) are described in Table 3.1. 
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Table 3.1: Nomenclatures of DISST model 
 
 
Variable Unit Description Role 
C pmol·L-1 Plasma C-peptide concentration measured 
I mU·L-1 Plasma insulin concentration measured 
G mmol·L-1 Blood glucose concentration measured 
Y pmol·L-1 
Interstitial C-peptide 
concentration 
simulated 
Q mU·L-1 Interstitial insulin concentration simulated 
QB mU·L
-1 Basal interstitial insulin 
concentration 
simulated 
UN mU·min
-1 Endogenous insulin secretion  
simulated/ 
deconvoluted 
k1, k2, k3 min
-1 C-peptide transport rates a-priori 
Vp L Plasma insulin distribution volume a-priori 
Vq L 
Interstitial insulin distribution 
volume 
a-priori 
nk min
-1 Renal insulin clearance rate a-priori 
nI L·min
-1 Plasma-interstitial diffusion rate a-priori 
nC min
-1 Interstitial insulin degradation 
rate 
a-priori 
Uex mU·min
-1 Exogenous insulin input rate a-priori 
Pt mmol·min
-1 Exogenous glucose input rate a-priori 
pgu min
-1 Non-insulin mediated glucose 
disposal rate 
a-priori 
αI L·mU
-1 Hepatic insulin clearance 
saturation parameter 
a-priori 
GB mmol·L
-1 Basal blood glucose concentration identified 
Vg L Glucose distribution volume identified 
nL min
-1 Hepatic insulin clearance rate identified 
xL 1 
Fractional first-pass hepatic insulin 
extraction 
identified 
SI L·mU
-1·min-1 Insulin sensitivity identified 
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3.3 Parameter identification 
3.3.1 2-parameter identification approach 
 
Initially, the DISST model uses a 2-parameter (x = [SI, VG]) identification approach when 
assessing the SI value, having made the assumption of G0 = GB. Previously, these participant-
specific parameter values of SI and VG were identified based on the physiological simulation 
of interstitial insulin and measured glucose data using the iterative integral method 
(Docherty et al. 2012). The glucose samples that were taken in the first 5 minutes after the 
glucose bolus were disregarded by the identification methods, as this period is heavily 
influenced by mixing kinetics that are not captured by the whole body model of glucose 
metabolism (Edsberg et al. 1987; Lotz et al. 2010). Linear interpolation was then used as an 
estimate of the glucose response to the test stimulus.  
 
In the identification procedure, the integral formulation of Equation 3.5 was rearranged and 
separated into the coefficients of the known and unknowns parameters, yielding: 
 
−𝑆𝐼∫ (𝐺𝑄 − 𝐺𝐵𝑄𝐵)
𝑡
0
𝑑𝑡
⏟            
𝐶𝑆𝐼
+
1
𝑉𝐺
∫ 𝑃𝑡𝑑𝑡
𝑡
0⏟    
𝐶𝑉𝐺
= 𝐺𝑡 − 𝐺0 +∫ 𝑝𝑔𝑢(𝐺 − 𝐺𝐵)𝑑𝑡
𝑡
0⏟                  
𝐶
 
(3.6) 
 
These coefficients of CSI, CVG and C were evaluated over the sample times from t = 0 until 
𝑡 = 𝑡1, 𝑡2, ⋯ , 𝑡𝑒𝑛𝑑 at the end of the test. These sample periods were chosen to minimise the 
fitting error and the variability of the identified insulin sensitivity (Docherty et al. 2011a). 
Subsequently, a matrix formulation was arranged to define the SI and VG terms, as defined:   
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[
 
 
 
 𝐶𝑆𝐼𝑡=0
𝑡=𝑡1 𝐶𝑉𝐺𝑡=0
𝑡=𝑡1
𝐶𝑆𝐼𝑡=0
𝑡=𝑡2 𝐶𝑉𝐺𝑡=0
𝑡=𝑡2
⋮
𝐶𝑆𝐼𝑡=0
𝑡=𝑡𝑒𝑛𝑑
⋮
𝐶𝑉𝐺𝑡=0
𝑡=𝑡𝑒𝑛𝑑]
 
 
 
 
[
−𝑆𝐼
1
𝑉𝐺
⁄ ] =
[
 
 
 
 𝐶𝑡=0
𝑡=𝑡1
𝐶𝑡=0
𝑡=𝑡2
⋮
𝐶𝑡=0
𝑡=𝑡𝑒𝑛𝑑]
 
 
 
 
 (3.7) 
where 𝑡𝑖 (𝑖 = 1, 2 … ) < 𝑡𝑒𝑛𝑑 capture different integration intervals. 
 
The values of VG are limited to identification of values within 12 to 25% of the participant’s 
bodyweight to reduce the effect incomplete mixing might have on the SI term (Defronzo et 
al. 1979; Ferrannini & Mari 1998; Lotz 2007; Lotz et al. 2010). However, while this 2-
parameter identification approach might be true for a more normoglycemic, healthy cohort, 
it may not hold in T2D or high insulin resistance.  
 
3.3.2 3-parameter identification approach 
 
Previous studies have suggested that GB and G0 should be treated as separate entities 
especially for individuals with established diabetes (Holman & Turner 
1977,1978,1979,1981). Hence, the participant-specific parameter values of GB, SI and VG can 
be identified in a 3-parameter identification approach by adapting the Gauss Newton 
parameter identification method (Björck 1996). The iteration function is defined: 
 
  
where 𝐱𝑖 = [𝐺𝐵𝑖 , 𝑆𝐼𝑖, 𝑉𝐺𝑖]
𝑇 and i is the iteration number. The Jacobian matrix (J) and the 
residual matrix (ψ) are defined: 
𝐱𝑖+1 = 𝐱𝑖 − (𝐉
𝐓𝐉)−1𝐉𝐓𝛙  (3.8) 
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where n is the number of measured samples, 
𝛿𝜓1
𝛿𝐺𝐵𝑖
 is the derivative of the residual matrix 
with respect to GB, G(xi,t1) is the modelled glucose concentration at t = t1 given xi, GS(t1) is 
the measured glucose level at t = t1.  
 
VG is similarly limited to within the range of 12% to 25% of participant’s body weight to 
avoid any parameter estimation issues. Equation 3.8 is iterated using Equation 3.9 until 
convergence to a tolerance. 
 
3.4 Summary 
 
With an assumption of G0 = GB, like most model-based assessments of SI employed, the SI 
value is well addressed by DISST model using a 2-parameter identification approach. 
However, previous studies have demonstrated that G0 is not equal to GB especially for 
individual with established diabetes. Hence, the original DISST model, while appropriate for 
more normoglycaemic cohorts, needs to model basal glucose level as a variable for 
assessing individuals with established T2D. This chapter presents the equations and 
rationale for a novel 3-parameter identification approach. 
  
𝐉(𝐱𝑖) =
[
 
 
 
 
 
 
 
𝛿𝜓1
𝛿𝐺𝐵𝑖
𝛿𝜓1
𝛿𝑆𝐼𝑖
𝛿𝜓1
𝛿𝑉𝐺𝑖
𝛿𝜓2
𝛿𝐺𝐵𝑖
𝛿𝜓2
𝛿𝑆𝐼𝑖
𝛿𝜓2
𝛿𝑉𝐺𝑖
⋮ ⋮ ⋮
𝛿𝜓𝑛
𝛿𝐺𝐵𝑖
𝛿𝜓𝑛
𝛿𝑆𝐼𝑖
𝛿𝜓𝑛
𝛿𝑉𝐺𝑖]
 
 
 
 
 
 
 
,         𝛙(𝐱𝑖) = [
𝐺(𝐱𝑖, 𝑡1) − 𝐺𝑆(𝑡1)
𝐺(𝐱𝑖, 𝑡2) − 𝐺𝑆(𝑡2)
⋮
𝐺(𝐱𝑖, 𝑡𝑛) − 𝐺𝑆(𝑡𝑛)
] (3.9) 
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Chapter 4. The necessity of identifying the basal 
glucose set-point in the Type 2 Diabetes 
 
This chapter underlines the importance of identifying GB as a variable, as opposed to other 
typical model-based SI assessments, where GB is set equal to G0. In particular, the impact of 
this approach is assessed for individuals with established T2D, where assessing SI accurately 
is important. 
 
4.1 Introduction 
 
The DISST is an alternative modelling approach that allows a lower intensity test compared 
to the IM-IVGTT that is often used to assess those with T2D and those with high insulin 
resistance (Bergman et al. 1979b; Ward et al. 2001). The DISST SI value is highly correlated 
to the EIC SI value (R=0.82), which is widely regarded as the reference method (McAuley et 
al. 2011). In particular, the DISST is able to produce highly repeatable SI metrics and also 
provides quantitative measures of UN via deconvolution of C-peptide data (Lotz 2007; Lotz 
et al. 2010; Lotz et al. 2008; McAuley et al. 2011).   
 
However, the DISST model and identification methods use the participant’s measured G0 as 
their GB setting GB = G0. The GB term in the DISST model effectively has the role of 
determining the set-point towards which the modelled glucose response moves. This choice 
thus matches assumptions in all other model-based tests (Bergman et al. 1979b; Bergman et 
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al. 1981; Bergman et al. 1987; Boston et al. 2003; Caumo et al. 1999). However, it is 
important to note that the DISST model was developed in a relatively healthy, 
normoglycemic cohort (Lotz ; Lotz et al. 2010). Hence, re-defining the role of GB as a variable 
in the DISST based approach to assessing SI could more clearly capture the observed 
glycaemic behaviour especially in T2D. 
 
More specifically, studies have shown that G0 levels and insulin concentrations are slightly 
higher in the morning than their overnight “basal” levels, especially for participants with 
established diabetes (Holman & Turner 1977,1978,1979,1981). Thus, the assumption of GB = 
G0 needs to be reviewed. In addition, prior evidence suggests that GB and G0 should be 
treated as separate entities for individuals with established diabetes as the levels are 
determined by relative insufficiencies in SI, UN, and rates of gluconeogenesis (Cahill 1971; 
Cahill et al. 1959; Steele et al. 1968).  
 
Hence, this chapter presents a novel modelling approach that identifies GB as a variable in a 
3-parameter identification (x = [GB, SI, VG]). The goal is to capture more accurate glucose 
dynamics, particularly for individuals with established type 2 diabetes. Results are thus 
expected to be improved over the 2-parameter identification approach, especially for T2D 
and highly insulin resistant cohorts. 
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4.2 Methods 
4.2.1 Participants 
 
Fourteen individuals with established type 2 diabetes mellitus were recruited from the 
Wellington region of New Zealand to take part in an Atkins-Based low carbohydrate dietary 
intervention study. Recruited participants were aged between 30 and 65 with a BMI range 
of 34 to 46 kg·m-2 at baseline.  Participants were excluded if they had major physiological or 
psychological illness at the time of testing. Pregnant or lactating females were also 
excluded.  Two participants discontinued the intervention, the first citing personal reasons, 
and the second left the study due to a renal stone. Twelve participants each underwent 
three IM-IVGTTs over a 24 week period resulting in a total of 36 data sets for the study. 
Participants had their age and BMI recorded (median [IQR]; 47.5 [42.5, 54.5] and 40.40 
[37.48, 43.48], respectively). Full demographic details and results of the intervention study 
have been previously described (Krebs et al.). Table 4.1 provides some further demographic 
data. Ethics approval for this study was provided by the New Zealand Ministry of Health, 
Central Regional Ethics Committee. 
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Table 4.1: Participant characteristics at baseline (W0) week 12 (W12) and the end of the trial 
at week 24 (W24) as well as their duration of diabetes. 
 
 
Participant 
Gender  
(M/ F) 
Age 
(yrs) 
Height 
(m) 
Weight (kg) Duration 
of diabetes 
(years) 
W0 W12 W24 
1 M 46 1.81 142.6 133.1 137.0 10 
2 M 56 1.79 130.8 121.1 114.4 1 
3 F 52 1.55 82.0 77.6 76.2 11 
4 F 55 1.71 121.7 111.7 108.7 6 
5 F 35 1.61 119.5 106.2 104.9 2 
6 M 56 1.79 145.3 140.6 135.9 5 
7 F 38 1.57 113.5 110.0 107.0 3 
8 F 45 1.59 95.6 87.6 86.6 7 
9 M 49 1.75 134.0 118.6 115.9 2 
10 M 41 1.71 128.0 127.0 132.3 4 
11 F 54 1.56 96.3 86.2 81.5 2 
12 M 44 1.80 130.7 123.5 122.8 0.5 
25% 
Median 
75% 
6 M 
6 F 
42.5 
47.5 
54.5 
1.58 
1.71 
1.79 
104.9 
124.9 
132.4 
96.9 
115.2 
125.3 
95.8 
111.6 
127.6 
2.0 
3.5 
6.5 
 
4.2.2 Clinical procedure 
 
The IM-IVGTT clinical protocol utilised in this study was similar to the protocol defined by 
Ward et al. (Ward et al. 2001). A 0.2 g·kg-1 glucose bolus was administered at t = 1 minute 
and then an infusion of insulin that was intended to replicate the insulinaemic response of a 
normoglycaemic individual was administered. An insulin infusion was started at t = 2 
minutes at a rate of 3.5 mU·kg-1·min-1 and was reduced to 0.5 mU·kg-1·min-1 at t = 7 minutes. 
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Further reductions occurred at t = 17 minutes, to 0.25 mU·kg-1·min-1, and at t = 50 minutes, 
to 0.1 mU·kg-1·min-1. The infusion of mU·kg-1·min-1 was maintained for the remainder of the 
procedure. Venous blood samples were taken and put into fluoride oxalate tubes at times: t 
= -10, -5, -1, 0, 2, 3, 4, 5, 6, 8, 10, 12.5, 15, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 120, 
140, 160, 180, 210, 240, 270 and 300 minutes. Blood samples were assayed for glucose and 
insulin concentration using standard commercial assays (Roche Diagnostics, New Zealand) at 
an accredited laboratory (Diabetes and Lipid Laboratory, University of Otago, Dunedin, New 
Zealand). 
 
4.2.3 Physiological model 
4.2.3.1 DISST Model 
 
With only glucose and insulin concentrations available from the clinical trial, the interstitial 
insulin kinetics and glucose dynamics of the DISST models was used (Lotz ; Lotz et al. 2010):  
 
?̇? = −(𝑛𝐶 +
𝑛𝐼
𝑉𝑄
)𝑄 +
𝑛𝐼
𝑉𝑄
𝐼 (4.1) 
?̇? = −𝑝𝑔𝑢(𝐺 − 𝐺𝐵) − 𝑆𝐼(𝐺𝑄 − 𝐺𝐵𝑄𝐵) +
𝑃𝑡
𝑉𝐺
 (4.2) 
  
where the equation nomenclature is well defined in Chapter 3, Section 3.2, Table 3.1. Note 
that 𝑉𝑄, 𝑛𝐼 and 𝑛𝐶  are defined a-priori based on anatomical functions (Barrett et al. 2009; 
Docherty 2011; Lotz et al. 2010; Van Cauter et al. 1992), while the DISST model sets 𝑝𝑔𝑢 as a 
constant at 0.004 min-1 (Lotz et al. 2010). 
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4.2.4 Parameter identification 
 
𝑄 was simulated via integrating factors and a linear interpolation of 𝐼.  
 
 𝑄 = 𝑒
−∫ 𝑛𝐶+
𝑛𝐼
𝑉𝑄
𝑡1
𝑡0
𝑑𝑡
(𝑄0 + ∫ 𝑒
∫ 𝑛𝐶+
𝑛𝐼
𝑉𝑄
𝑡1
𝑡0
𝑑𝑡𝑡1
𝑡0
𝑛𝐼
𝑉𝑄
𝐼𝑑𝑡) (4.1a) 
 
where 𝑄0 is determined assuming a steady state at t = -10 minutes: 
𝑄0 =
𝑛𝐼
𝑉𝑄
𝐼0
𝑛𝐶 +
𝑛𝐼
𝑉𝑄
 (4.3) 
The DISST model typically sets 𝐺𝐵 = 𝐺0 (Lotz ; Lotz et al. 2010). Hence, 𝐺0 acts as a surrogate 
basal glucose concentration level. However, for individuals with elevated fasting glucose, 
this assumption may not be accurate (Holman & Turner 1977,1978,1979,1981), and is 
tested in this study.  
 
In this analysis, 𝐺𝐵 was identified in concert with 𝑆𝐼 and 𝑉𝐺. The typical approach used with 
the DISST model identifies only SI and VG. Thus, the outcomes of the 3-parameter 
identification approach (x = [GB, SI, VG]) model can be compared to the outputs of the typical 
2-parameter identification approach (x = [SI, VG]). A Gauss Newton parameter identification 
method was used to identify these 3 parameters. A full detailed description of the 
identification methodology via Gauss Newton method was previously discussed in Chapter 
3, Section 3.3.2.  
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The Jacobian was numerically evaluated using perturbations of [𝛿𝐺𝐵 , 𝛿𝑆𝐼, 𝛿𝑉𝐺] =
[10−3, 10−8, 10−3]. These perturbation values were 0.1% of the order of magnitude of the 
expected parameter values. Glucose samples between t = 1 and t = 10 minutes were 
disregarded by the identification methods, as this period is heavily influenced by mixing 
kinetics that are not captured by the whole body model of glucose metabolism (Edsberg et 
al. 1987; Lotz et al. 2010).  
 
Identifying GB in concert with SI and VG can cause identified parameter trade off in some 
cases (Docherty et al. 2011a). The value of VG was thus limited to physiologically measured 
bounds from other studies (Defronzo et al. 1979; Ferrannini & Mari 1998; Lotz 2007; Lotz et 
al. 2010). In particular, VG was limited to the range of [0.12Bw, 0.25Bw] where bodyweight 
(Bw) is measured in kg and the coefficients have units of l·kg-1, which is a standard 
estimation approach linking volume to an easily measured value. Similarly, GB was limited to 
a minimum of 3 mmol·L-1. Both sets of limits are physiologically outside normal published 
bounds, but do not allow non-physiological results, such as negative or very small GB or 
volume. 
 
4.3 Statistical analysis 
 
Identified model residuals compared to the clinical data and interpretation of population 
trends were used to assess the performance of the GB identified - DISST model. The p-values 
are defined with signed ranksum (prs) and Kolmogrov Smirnov test (pks) to assess median 
and variability of non-parametric non-Gaussian distributions. A Pearson correlation (R value) 
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is used in the analysis to show the linear relationship between two sets of data. All analysis 
was undertaken using MATLAB (R2013b, Mathworks, Inc., Natick, MA, USA). 
 
4.4 Results 
 
Table 4.2 shows the tabulated data comparing the 2- and 3- parameter identification 
approaches across all 36 tests over 24 weeks of the clinical study. It can be clearly seen that 
adopting the 3-parameter identification approach in assessing the SI value lead to significant 
differences between the measured G0, identified basal glucose (GB-ID), and resulting 
identified SI values between the two identification approaches. Although, there is no 
significant different in variability for VG values as pks (Kolmogorov Smirnov) = 0.2975, the 
medians are significantly difference since prs (Signed-ranksum) < 0.00001. 
 
Figures 4.1 and 4.2 show the individual relationships between G0, GB-ID and identified SI from 
the 2- and 3- parameter identification approaches for the DISST model across all participants 
and tests. Note the bias about the 1:1 line indicating that on average, the identified, model-
based basal set point for glucose (GB-ID) was significantly lower than the fasting rate (G0) for 
this cohort with diabetes. Figure 4.1 shows there were significant differences in median and 
variability between the G0 and GB-ID values in this cohort (prs<0.0001, pks<0.0001). In general, 
G0 was higher than the GB-ID value, with only 4 exceptions over 36 results (11.1%). Although 
there was a significant difference in the levels of GB-ID and G0, they were relatively well 
correlated (R=0.70), indicating a moderately consistent bias in the relationship between 
values.  
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Table 4.2: Tabulated data of G0, GB-ID, SI and VG identified from two modelling approaches 
across 36 tests. 
 
 2-parameter identification 3-parameter identification 
 G0 
[mmol·L-1] 
SI 
[×10-4 L·mU-
1·min-1] 
VG 
[L] 
GB-ID 
[mmol·L-1] 
SI 
[×10-4 L·mU-
1·min-1] 
VG 
[L] 
 16.85 3.27 35.65 9.59 0.34 35.65 
 6.67 3.14 26.03 7.54 3.08 32.70 
 16.33 7.80 11.38 11.48 2.71 14.99 
 7.73 7.88 28.14 5.38 4.35 30.43 
 8.50 9.27 28.23 5.57 4.39 29.88 
 7.51 2.18 30.50 8.53 2.71 33.48 
 14.42 6.01 23.13 9.29 1.95 28.38 
 6.64 22.85 14.95 3.95 11.56 16.48 
 9.07 1.92 33.50 6.24 0.78 33.50 
 6.62 5.19 31.30 4.27 2.29 32.00 
 7.25 8.61 12.14 4.67 3.59 16.25 
 8.58 5.23 24.08 5.76 2.31 29.15 
 11.36 1.93 29.04 9.14 0.96 33.28 
 6.05 4.89 23.52 5.60 4.13 25.57 
 10.33 8.17 11.10 3.00 1.32 12.14 
 6.62 11.59 20.40 4.29 6.57 23.79 
 6.75 8.51 26.55 3.57 3.15 26.55 
 7.09 2.12 33.82 6.38 2.73 33.14 
 12.62 5.95 23.29 9.42 2.82 27.50 
 6.51 26.11 13.45 3.43 11.33 15.25 
 5.12 4.85 29.65 4.11 3.57 29.65 
 5.60 6.21 31.75 5.77 7.05 28.31 
 6.96 7.87 13.08 4.64 5.20 13.98 
 6.64 10.27 22.81 5.30 7.09 22.75 
 11.72 2.96 26.83 9.69 1.15 34.25 
 5.91 6.01 17.76 3.86 3.82 18.75 
 10.80 11.17 9.14 3.51 2.50 11.91 
 6.69 10.48 27.17 5.94 8.50 27.18 
 7.60 9.50 20.51 3.51 2.62 25.52 
 6.74 3.21 29.70 7.57 3.89 33.98 
 9.96 6.50 23.01 6.58 1.79 26.75 
 6.76 16.67 11.87 4.65 10.24 14.08 
 6.09 5.34 28.97 5.33 4.70 27.15 
 9.92 6.26 21.37 5.53 1.47 25.23 
 6.39 12.00 11.83 5.43 7.62 15.52 
 7.22 7.82 21.30 5.37 4.47 26.37 
25% 6.63 4.87 16.36 4.28 2.30 17.61 
Median 7.16 6.38 23.41 5.48 3.36 26.95 
75% 9.94 9.39 29.01 7.06 4.95 31.21 
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Figure 4.1: Relationship between G0 and GB-ID across tests. The 1:1 G0 = GB-ID line (dots) is to 
show the bias between approaches. The solid line has R=0.70. 
 
Figure 4.2 shows the effect that identifying GB-ID has on the identified SI values in the 3-
parameter approach. There is a reasonably strong correlation between the SI values 
between the 2- and 3- parameter identification of the DISST model (R=0.83). The bias 
indicates that by identifying basal glucose, the model captures consistently lower SI values 
for those with established T2D. 
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Figure 4.2: Relationships between SI values of 2- and 3- parameter identification approach 
across tests. The 1:1 line (dots) is to show the bias between approaches. The solid line has 
R=0.83. 
 
Figure 4.3 shows the fitted glucose profiles and measured glucose data from 3 different 
participants. It also shows that the identified GB-ID levels are well below the measured G0 
values, as depicted in Figure 4.1. Figure 4.4 illustrates the residual errors for all 36 tests of 
both the typical DISST model and the proposed three parameter identified model that 
identifies basal glucose. Note again that the glucose samples taken within 10 minutes of 
glucose injection were ignored due to un-modelled mixing effects. 
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Figure 4.3: Blood glucose participant-specific profile (G(t)) for participants 2, 7, 10 with 2- 
and 3- parameter identification approach. 
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Figure 4.4: Residual error (mean and standard error, 𝑆𝐸 =
𝑆𝐷
√𝑁
) between the measured 
glucose data and the response model by Equation 2 for all 36 tests. The residuals reflect 
model accuracy after bolus dosing and mixing errors are passed. 
 
4.5 Discussion 
 
This analysis is the first study to demonstrate that glucose excursions are more accurately 
modelled using basal glucose as an identified variable in the DISST model, rather than 
assuming fasting glucose G0 = GB for individuals with established type 2 diabetes. The typical 
approach employed when using the DISST model defines the G0 as equal to the GB. Hence, 
the glucose response defined by the original model typically tends towards the measured 
basal value (G0).  
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However, this analysis has shown that this assumption is not valid for a cohort with 
established diabetes. This discrepancy in the assumption is evidenced by the significant 
distinction in the values of G0 and GB. In addition, this discrepancy reduces as participant 
glycaemic control improved across the 24 weeks of the dietary intervention study (Krebs et 
al.). Figure 4.1 shows that while most participants had elevated G0 levels, the GB-ID was often 
much closer to the lower value seen in healthy subjects. In particular, 14 of the 36 identified 
GB values were in the normal reference range of 4-5.6 mmol∙L
-1 (ADA), while only 2 of 36 
measured G0 values were in that range.  
 
However, there were some participants for whom GB-ID remained very high throughout the 
intervention. Of the three participants that exhibited GB-ID values greater than 9 mmol·L
-1, 
two were first diagnosed 10 years prior to this trial. In contrast, the mean duration of 
diabetes for the whole cohort was 4.4 years (SD=1.0 year) and median was 3.5 years. This 
outcome indicates a possible mechanism of dysfunction in type 2 diabetes that develops 
during the course of the disease, and matches the well-known growth of dysfunction over 
time in T2D individuals. However, while this study lacks the numbers required for conclusive 
proof of this trend, it does show the ability of the improved identification approach to 
better capture expected metabolic behaviour. 
  
Figure 4.2 shows the effects of SI values when identified the GB values used are significantly 
lower than the measured G0 values for these type 2 diabetes participants. Hypothetically, if 
models set GB = G0, SI will be used in the model to account for low glucose levels, rather 
than GB and is thus identified in the 2-parameter case as a higher SI value. A recent study 
shows that type 2 diabetes subjects have SI values in the magnitude of 1-4×10-4 L·mU-1·min-1 
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(Lotz 2007). Although, there is not enough evidence to prove a precise range of SI value for 
type 2 diabetes participants, it is understandable that lower SI value contributes to the 
pathogenesis of type 2 diabetes as SI is inversely proportional to IR (Ferrannini 1997). 
Hence, there is good reason to believe that the lower GB-ID values are real and realistic based 
on current knowledge. 
 
Figure 4.3 shows the blood glucose profiles of three participants as modelled by the typical 
2-parameter (x = [SI, VG]) and 3-parameter (x = [GB, SI, VG]) DISST identification approach. 
While the typical 2-parameter DISST identification fails to fully capture the responses of 
these participants, the amended 3-parameter identification method captures the observed 
behaviours more closely. This outcome is confirmed by the residual plots in Figure 4.4 that 
indicate a much smaller, more consistent trend about the measured data. This change 
implies the modified model captures previously un-modelled effects due to poor a-priori 
estimates in the model that are rectified by identifying 3 parameters instead of 2.   
 
The original DISST model was developed (Lotz et al. 2010) and validated (McAuley et al. 
2011) primarily in relatively normoglycaemic and glucose tolerant cohorts. In these cohorts, 
the incidence of impaired fasting glucose was relatively low, and thus, the assumption GB = 
G0 was well founded. However, the glycaemic behaviour of the cohort used in this analysis 
showed that this assumption was most not valid in these participants. In particular, the 
lower glucose levels achieved in the later part of the test would be falsely attributed to 
increased insulin sensitivity, rather than a GB value that was lower than G0. The significantly 
biased residuals in Figure 4.4 validate the outcome where they show that the typical DISST 
model cannot capture all the dynamics of this T2D cohort without identifying GB directly. 
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Overall, these results indicate that the original 2-parameter approach, while appropriate for 
normoglycaemic and mild intolerant cohorts (Lotz ; Lotz et al.), is less suitable for highly 
insulin resistant individuals with established type 2 diabetes. Furthermore, it is unknown 
how much the outcomes of this study would be applicable to pre-diabetic individuals that 
have elevated blood glucose. Hence, this assertion remains to be determined. 
 
Neither DISST identification approach accurately captures the peak value of the measured 
blood glucose data. This particular result was due to the disregarded glucose data within 10 
minutes of glucose injection. This data was rejected due to the unmodelled effects of 
intravascular mixing (Edsberg et al. 1987). A second compartment to model local/global 
mixing kinetics could be added. However, this addition was deemed unnecessary, as such 
compartments do not add value to the DISST modelled outcomes (Lotz et al. 2010). The 
approach used was intended to avoid over-fitting and/ or over-modelling of mixing effects. 
 
Although, this analysis was done in a small test cohort, the outcomes are significant as it has 
shown that GB is an important variable when modelling the glycaemic behaviour in 
established type 2 diabetes. It also showed that GB can be quite different to the typically 
assumed G0 value used in all other studies, and that it may also have some diagnostic value. 
These findings suggest that the GB value should be treated as a variable in DISST model 
identification for this cohort. Further validation in a much larger cohort will provide a 
broader foundation for these findings.  
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4.6 Summary 
 
This analysis has shown the presence of a dysfunction in the basal (set-point) glucose in 
individuals with type 2 diabetes. The magnitude of the dysfunction has been shown to be 
linked to insulin sensitivity and the degree of fasting glucose. This analysis suggests that the 
basal glucose is a more appropriate variable for individuals with type 2 diabetes, as using 
the fasting glucose measurement as the basal set-point was shown to be a poor assumption 
for this cohort - although this requires confirmation in a larger study with a clamp as the 
reference. 
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Chapter 5. Impact of identifying the basal glucose set-
point on model-based assessment of insulin 
sensitivity 
 
This chapter portrays the influence of identifying the basal glucose set point as a variable 
towards assessing SI. It is particularly targeted for individuals with established T2D, where 
model-based SI tests often fail or suffer poor resolution. 
 
5.1 Introduction 
 
SI is widely regarded as an important index that quantifies the body’s ability to lower blood 
glucose concentration with insulin and is one of the key element in the pathogenesis of type 
2 diabetes (Pacini & Mari 2003). The pathogenesis of T2D progresses through 3 distinct 
stages: 1) NGT; 2) IGT; and 3) T2D (Pories & Dohm 2012). Typically, SI reduces during the 
progression of type 2 diabetes (Hanley et al. 2003; Ingelsson et al. 2005; Martin et al. 1992; 
Zethelius et al. 2004). A NGT individual will have a high value of SI, while a T2D will have a 
lower value of SI.       
 
The DISST was designed to capture high resolution estimates of participant-specific SI and 
UN profiles (Lotz 2007; Lotz et al. 2010; McAuley et al. 2011). The DISST compares 
favourably with the gold standard EIC in assessing SI with strong correlation of R = 0.82 
(McAuley et al. 2011). Like most model-based assessments of SI and IR (Bergman et al. 
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1979b; Bergman et al. 1981; Bergman et al. 1987; Boston et al. 2003; Caumo et al. 1999), 
the DISST model approach uses the participant’s measured G0 as their modelled GB so that 
G0 = GB. However, previous studies have shown that G0 levels and insulin concentrations are 
slightly higher in the morning than their overnight levels, especially for diagnosed diabetes 
participants (Holman & Turner 1977,1978,1979,1981). This evidence suggests that GB is not 
fully represented by G0, especially for these individuals. 
 
However, whether G0 and GB should be treated as separate entities has yet to be 
determined for any cohort. In addition, it is not known whether identifying GB in the DISST 
model would lead to a better result in assessing the SI value.  This chapter uses a new 
parameter identification approach to evaluate the impact on the identified SI value from a 
model-based SI assessment when acknowledging GB as an identified model variable in a 
cohort of individuals with type 2 diabetes. 
 
5.2 Methods 
 
A total of 36 full test IM-IVGTT data sets, recorded from 12 participants in a 24-week dietary 
intervention study, were used to further analyse the efficacy of SI value between measured 
G0 and identified GB in a 2- and 3- parameter identification approaches. A full detailed 
description of the identification methodology was well discussed in Chapter 4, Section 4.2. 
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5.3 Statistical analysis 
 
The median and variability of SI and GB values are compared using the signed ranksum (prs) 
and Kolmogrov Smirnov (pks) tests, respectively. The signed ranksum test compares the 
specific participant matched SI results from the 2- and 3- parameter identification 
approaches. In addition, the Kolmogrov Smirnov (KS) test is sensitive to differences in both 
location and shape of the empirical cumulative distribution functions of SI distributions from 
the two approaches. P-values less than p < 0.05 were considered significant. All analysis was 
undertaken using MATLAB (R2013b, Mathworks, Inc., Natick, MA, USA). 
 
5.4 Results 
 
Table 5.1 contrasts measured G0 values and identified GB values across the participants and 
weeks of testing as well as the SI values identified across the two identification approaches. 
There were significant differences between the pooled patient- and week- specific G0 and 
identified GB values in this cohort (Signed ranksum: prs<0.0001, Kolmogorov Smirnov: 
pks<0.0001). Although there was a significant difference in the magnitudes of GB and G0, 
they were relatively well correlated (R=0.70), indicating a moderately consistent bias in the 
relationship between the measured and identified values. A similar trend can be seen for 
the identified SI values from the typical 2-parameter (x = [SI, VG]) and 3-parameter (x = [GB, 
SI, VG]) identified models. In particular, there were significant differences across the two 
identification approaches in identified SI values (Signed ranksum: prs<0.0001, Kolmogorov 
Smirnov: pks<0.0001) with a stronger correlation of R=0.83. 
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Table 5.1: Tabulated data of initial G0, GB, SI identified from two modelling approaches 
across all participants. 
 
Participant 
G0 [mmol·L
-1
] GB [mmol·L
-1
] 
SI2-parameter DISST 
 [×10
-4
 L·mU
-1
·min
-1
] 
SI3-parameter DISST 
 [×10
-4
 L·mU
-1
·min
-1
] 
W 0 W 12 W 24 W 0 W 12 W 24 W 0 W 12 W 24 W 0 W 12 W 24 
1 16.85 11.36 11.72 9.59 9.14 9.69 3.27 1.93 2.96 0.34 0.96 1.15 
2 6.67 6.05 5.91 7.54 5.60 3.86 3.14 4.89 6.01 3.08 4.13 3.82 
3 16.33 10.33 10.80 11.48 3.00 3.51 7.80 8.17 11.17 2.71 1.32 2.50 
4 7.73 6.62 6.69 5.38 4.29 5.94 7.88 11.59 10.48 4.35 6.57 8.50 
5 8.50 6.75 7.60 5.57 3.57 3.51 9.27 8.51 9.50 4.39 3.15 2.62 
6 7.51 7.09 6.74 8.53 6.38 7.57 2.18 2.12 3.21 2.71 2.73 3.89 
7 14.42 12.62 9.96 9.29 9.42 6.58 6.01 5.95 6.50 1.95 2.82 1.79 
8 6.64 6.51 6.76 3.95 3.43 4.65 22.85 26.11 16.67 11.56 11.33 10.24 
9 9.07 5.12 6.09 6.24 4.11 5.33 1.92 4.85 5.34 0.78 3.57 4.70 
10 6.62 5.60 9.92 4.27 5.77 5.53 5.19 6.21 6.26 2.29 7.05 1.47 
11 7.25 6.96 6.39 4.67 4.64 5.43 8.61 7.87 12.00 3.59 5.20 7.62 
12 8.58 6.64 7.22 5.76 5.30 5.37 5.23 10.27 7.82 2.31 7.09 4.47 
25% 
Median 
75% 
6.96 
8.11 
11.75 
6.28 
6.69 
8.71 
6.54 
6.99 
9.94 
5.02 
6.00 
8.91 
3.84 
4.97 
6.07 
4.25 
5.40 
6.26 
3.20 
5.62 
8.24 
4.87 
7.04 
9.39 
5.67 
7.16 
10.82 
2.12 
2.71 
3.97 
2.78 
3.85 
6.81 
2.14 
3.86 
6.16 
 
 
Figure 5.1 shows the individual relationships between G0 used in the 2-parameter 
identification and identified GB from the 3-parameter identification for all participants and 
weeks. Note the bias about the 1:1 line indicating that, in almost all cases, the identified GB 
value was significantly lower than G0 for this cohort with diagnosed type 2 diabetes. There 
were only 4 exceptions over 36 results (11.1%) where G0 < GB. 
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Figure 5.1: Relationship between G0 and identified GB across all participants and weeks. 
 
 
Figure 5.2 exhibits a significant reduction in SI values from the 3-parameter identification 
compared to the typical 2-parameter identification approach. Table 5.1 shows that the 
highest SI value identified by the 3-parameter case was 11.56×10-4 L·mU-1·min-1, compared 
to 26.11×10-4 L·mU-1·min-1 for the 2-parameter case. Figure 5.3 shows the distribution of G0 
and identified GB across SI values from the two modelling approaches. 
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Figure 5.2: Relationships between SI values identified from the typical 2-parameter (x = [SI, 
VG]) and 3-parameter (x = [GB, SI, VG]) DISST model across all participants and weeks. 
 
Figure 5.4 shows the fitted blood glucose models against the measured glucose data for 
Participants 2 and 10. It shows the impact of adopting G0 = GB in the 2-parameter case and 
identifying GB in the 3-parameter case. For Participant 2 in week 12 the identified GB value 
was similar to the G0 value and thus, there was minimal difference in the simulations or SI 
values (left panel vs right panel). In contrast, Participant 10 exhibited a much larger 
discrepancy between GB and G0. Hence, this participant’s simulations and SI values across 
models were quite different. 
 
0 5 10 15 20 25 30
0
5
10
15
20
25
30
1 2
3 4
5
6
7
8
9
10
11
2
(1
:1
 li
ne
)
SI
3-parameter DISST
 [10
-4
L.mU
-1
.min
-1
]
S
I 2
-p
a
ra
m
e
te
r 
D
IS
S
T
 [
1
0
-4
L
.m
U
-1
.m
in
-1
]
 
 
P1
P2
P3
P4
P5
P6
P7
P8
P9
P10
P11
P12
54 
 
 
Figure 5.3: Distribution of fasting and identified basal glucose concentration and identified 
insulin sensitivity between the 2-parameter (x = [SI, VG]) and 3-parameter (x = [GB, SI, VG]) 
DISST model. 
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Figure 5.4: Blood glucose participant-specific profile (G(t)) for Participants 6 and 10 with 
typical 2-parameter and 3-parameter identification of the DISST model. 
 
Figure 5.5 shows the discrepancy in SI values across the two identification approaches. The 
bias in SI values across the two model approaches was -3.16 x10-4L·mU-1·min-1 (IQR: -10.50 
to 0.66 x10-4L·mU-1·min-1). 
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Figure 5.5: Bland Altman plot of insulin sensitivity values from 2- and 3- parameter 
identification approaches of DISST model. 
 
5.5 Discussion 
 
Typical model-based identification of SI sets G0 as the basal blood glucose level, GB, that the 
glucose level tends towards (Bergman et al. 1979b; Bergman et al. 1981; Bergman et al. 
1987; Boston et al. 2003; Caumo et al. 1999; Docherty 2011; Lotz 2007; Lotz et al. 2010; Lotz 
et al. 2008; McAuley et al. 2011). However, this study finds a significant distinction between 
fasting G0 and “set-point” GB glucose concentration for these insulin resistant participants. 
The results suggest that GB should be identified as a variable during the modelling of 
glycaemic data from individuals with type 2 diabetes, when using the DISST or similar 
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model. Furthermore, the findings indicate a possible mechanism of dysfunction for 
individuals with longer term established type 2 diabetes. 
 
Figure 5.3 shows the impact of G0 and GB in assessing the SI value. In broad terms, when the 
model is fit to the clinical data, increasing GB is compensated by higher SI values. Hence, 
setting GB = G0, where this analysis finds GB < G0 (p < 0.001), will yield higher SI values. The 
typical model thus effectively captures a low glucose level as an effect of SI, rather than (a 
lower than assumed) GB.  
 
Identification of GB thus proves crucial in identifying a more representative value of SI for 
this cohort using this model. In particular, for this insulin resistant cohort, use of a lumped 
parameter SI, that is representative of both peripheral and hepatic insulin sensitivity, is best 
modelled in conjunction with GB as an identified variable. However, there was no evidence 
to support the necessity of identifying GB in healthy cohorts, where the assumption of GB = 
G0 by other model-based identification of SI is much more accurate (Beard et al. 1986; Pacini 
et al. 1998). 
 
Figure 5.4 shows blood glucose profiles (G(t)) fitted by the two identification approaches. As 
Participant 10 has G0 > GB, the fit-to-data is much better for the 3-parameter identification 
(Median absolute residual error (RE) = 0.0800 mmol·L-1) than the 2-parameter case (RE = 
0.5233 mmol·L-1) where the RE was   7̴× larger. Hence, it is clear that assuming GB = G0 in the 
model has not captured the behaviour of this dataset particularly well, and the identified 
model with the 2-parameter approach is thus not fully representative of the patient state.  
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However, if G0 ≈ GB as in Participant 2, the fitted G(t) profiles from both models were well 
calibrated against the measured glucose data. The RE of fitted (G(t)) profile and measured 
glucose data is 0.1657 mmol·L-1 compared to 0.1350 mmol·L-1 for the 2- and 3-parameter 
cases, respectively. This result implies that, when the G0 ≈ GB the adapted model 
identification approach provides minimal benefit and no impediment and thus, the SI values 
across the approaches are equivalent. However, it is important to note, that one does not 
know if G0 ≈ GB until after the 3-parameter identification is performed. Thus, the approach 
should be used in either case. 
 
Table 5.1 shows that while most participants had elevated G0 glucose levels, GB was 
identified closer to a normal reference range of 4-5.6 mmol∙L-1 (ADA). In particular, 14 of the 
36 GB values (38.9%) identified were in the normal range, while only 2 of 36 G0 values (5.6%) 
were in that range. Figure 5.1 shows that G0 was typically higher than identified GB, with 
only 4 exceptions over 36 results (11.1%). This result implies that most individuals with type 
2 diabetes have a lower set point GB level than assumed by G0 and would thus attain lower 
glucose levels if sufficient exogenous insulin and/or longer-term fasting was introduced 
(Ciampolini et al. 2010).  
 
The Bland Altman plot in Figure 5.5 implies that the bias is not equal to a constant value of -
3.16 x10-4. A random variation of data around slope of -0.64 can be clearly seen. However, it 
can be said that, the SI value identified by 3-parameter is significantly lower compare to 2-
parameter identification approach particularly at SI value > 10 ×10-4 L·mU-1·min-1. However, 
this figure is well affected by Participant 8. SI values for Participant 8 across the clinical study 
in Table 5.1 shows that while 2-parameter approach identified SI in wider range of 16 – 
59 
 
26×10-4 L·mU-1·min-1, the 3-parameter approach identified in much narrow range of 10 – 
12×10-4 L·mU-1·min-1. This indicates an inconsistent value of SI will be identified when 
adopting the assumption G0 = GB particularly for established T2D participant.     
 
Throughout the study, Participant 8 maintained relatively high values of SI compared to 
other participants. This participant had been diagnosed with diabetes 7 years prior to the 
study. The high values of SI imply that their diabetes is predominantly driven by an inability 
to produce sufficient insulin. This lack of insulin ultimately led to high fasting glucose levels 
(G0 in Table 5.1, Figure 5.1). However, when increased levels of insulin were introduced by 
the IM-IVGTT, the participant’s glycaemic response tended towards a value much lower 
than the fasting value of G0 and towards the identified GB ≈4mmol∙L
-1 and GB < G0 that was 
found for that participant.  
 
Table 5.1 shows that Participant 10 experienced a modest weight loss between week 0 and 
week 12 (0.8%) that was concurrent with an improved in SI value. However, after week 12 
the participant failed to comply the diet and gained 4.2% body weight over the second 
period. Hence, the SI of Participant 10 fell between week 12 and week 24. This result aligns 
with the general trend of improved SI due to weight loss (Camastra et al. 2005; Ferrannini et 
al. 2005). Throughout the study, Participant 10 had consistent identified GB values within 
the healthy range. In contrast, their G0 values at week 0 and 12 were slightly elevated, and 
the week 24 G0 was a highly elevated 9.92 mmol∙L
-1. This result shows that while the change 
in diet had a quick effect on the fasting glucose, the GB remained healthy throughout the 
intervention. Hence, the adapted 3-parameter model identification approach captured an 
underlying and important aspect of this participant’s metabolic response.  
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Participant 11 achieved improvements in every aspect as a result of the intervention. In 
particular, their body weight dropped, SI improved, and G0 improved. Changes in GB were 
minimal for this participant but GB < G0 was true throughout the intervention. However, by 
identifying GB, the SI values of this participant were altered. Inspection of the SI values from 
the simple 2-parameter identification of the DISST model does not exhibit the expected 
improvement in insulin sensitivity for this participant. Thus, setting GB = G0 potentially 
obscured improvements in SI that were elucidated by the 3-parameter model identification. 
 
Glycaemic responses of healthy individuals tend toward the fasting level. Nine of the 12 
participants had glycaemic responses that tended towards a healthy basal GB value, despite 
all participants having impaired fasting glucose at week 0. Two of the 3 individuals 
(Participants 1, 3, 7) that had elevated identified GB values had long-term diabetes. These 
latter results may imply that the basal set point of glycaemia could be a late onset 
dysfunction of the disease – although greater participant numbers would be required to 
confirm this outcome. 
 
Figure 5.2 shows that the identified SI values from the 3-parameter identification are 
significantly lower than for the typical 2-parameter identification, with only 4 exceptions 
over 36 results (11.1%). Although, there is no accepted range of SI values used to diagnose 
participants with T2D, the 3-parameter model identified values in the range of 2 - 4×10-4 
L·mU-1·min-1 are more in line with previous findings (Lotz 2007). This outcome shows that 
when GB is not an identified variable, the participants’ glycaemic dynamics are potentially 
wrongly attributed to SI, and that identification of GB provides a more clinically 
representative result. 
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5.6 Summary 
 
Identifying GB, SI and VG as model variables in a 3-parameter identification allows greater 
descriptive ability of the metabolism of individuals with type 2 diabetes and is thus a 
necessary modification for using the DISST model for this cohort, and in general since no 
accuracy is last when GB ≈ G0. The assumption of GB = G0 effects the typical 2-parameter 
identification and results by leading to potentially erroneous SI values or SI changes from an 
intervention. This analysis has shown that it is important to model the basal glucose value as 
a variable when assessing the SI value for individuals with type 2 diabetes, and presented a 
new effective 3-parameter identification approach to accomplish that task.  
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Chapter 6. Model-based identification of endogenous 
insulin secretion  
 
This chapter discusses the development of a model to identify patient-specific UN 
parameters. The modelling approach will link UN to changes in glucose concentration in a 
feedback control modelling framework. In contrast, UN profiles are typically derived via 
direct inversion or deconvolution of interpolated measured values of C-peptide 
concentration.  
 
6.1 Introduction 
 
Although the pathogenesis of type 2 diabetes varies, the common route includes failure of 
pancreatic β-cells to compensate for IR (Breda et al. 2002; Ferrannini 1997; Kahn 1998; Mari 
et al. 2002; Pories & Dohm 2012). The inability to produce sufficient insulin to meet demand 
results in elevated glucose concentrations. However, this elevation in glucose concentration 
does not occur until the insulin demand exceeds the maximal possible insulin secretion rate, 
which only arrives in the later stages of the pathogenesis of type 2 diabetes and well after 
initial pathological changes in UN has occurred (Ferrannini 1997; Pories & Dohm 2012). Thus, 
diagnosis based solely on IR can miss the early stages of dysfunction. 
 
Thus, measuring endogenous insulin secretion may enable earlier diagnosis of metabolic 
dysfunction, long before elevated glucose occurs, which in turn would allow earlier, possibly 
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more effective intervention. Many studies have been conducted to determine the best 
technique for identifying the participant’s glycemic condition by measuring their insulin 
secretion and insulin sensitivity (Albareda et al. 2000; Bergman et al. 2002b; Lotz et al. 2010; 
Mari et al. 2005; McAuley et al. 2007). Unlike SI, there is no gold standard for the 
measurement of β-cell function or UN. Thus, most secretion studies use deconvolution of C-
peptide concentration measurements to identify participant-specific UN profiles (Eaton et al. 
1980; Polonsky et al. 1986; Van Cauter et al. 1992), which is a de-facto standard approach.  
 
The deconvolution method is effective due to the fact that insulin and C-peptide are co-
secreted in an equimolar fashion from the β-cells in the pancreas (Rubenstein et al. 1969). 
While the pharmacokinetics of insulin are complex, the pharmacokinetics of C-peptide are 
much simpler. Hence, the process of identifying UN via C-peptide concentration is crucial. In 
particular, insulin undergoes a substantial first pass hepatic extraction before reaching the 
peripheral circulation. In addition, clearance via glucose uptake in the cells is another 
clearance route that is highly variable. This extraction inhibits the modelling of UN directly 
from insulin measurements due to the added, unknown variability and may lead to 
misidentification of UN (Hovorka & Jones 1994; Polonsky & Rubenstein 1986). Thus, the 
single, well defined kidney clearance of C-peptide provides a more suitable basis for 
estimating UN.    
 
This chapter presents a novel PD control model of UN to estimate participant-specific UN 
profiles, as opposed to identification based on a deconvolution approach, which relies on 
frequent, costly C-peptide sampling to capture all the dynamics. The PD control UN model is 
developed to provide an estimation of participant-specific UN profiles based on a 
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physiological model of human body’s closed-loop system in controlling the set of rate of 
insulin secretion in respond to glucose concentration. It also allows for more sparse C-
peptide sampling by providing smooth, physiologically relevant dynamics between 
measurements. 
 
6.2 Existing deconvolution approach 
 
As the concentration of glucose in bloodstream rises, it triggers a response to the β-cell in 
the islet of Langerhans within the pancreas (Figure 6.1) to produce and secrete insulin 
(Cherrington 1999). The release of insulin expedites glucose uptake from blood stream into 
the tissue cells. This endogenous insulin secretion (UN) plays a key role in regulating blood 
glucose concentration to a normal, healthy level of 4 – 5.6 mmol.L-1 (ADA 2014).  
 
Prior studies have shown that insulin is formed from proinsulin, a single-chain polypeptide 
precursor (Steiner et al. 1967; Steiner & Oyer 1967). However, like insulin, C-peptide, is also 
produced by the pancreatic β-cells (Despopoulos & Silbernagl 2003; Guyton & Hall 2006). In 
addition, C-peptide is also originated from the proinsulin and is recognised as a by-product 
of insulin (Chevenne et al. 1999). 
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Figure 6.1: Physiologic anatomy of an islet of Langerhans in the pancreas. Adapted from 
(Guyton & Hall 2006).  
 
Figure 6.2 illustrates the 86-amino-acid precursor proinsulin. This precursor proinsulin is 
cleaved internally to yield C-peptide (31 amino acids) and the A (21 amino acids) and B (30 
amino acids) chains of insulin, which are connected by disulfide bonds (Chevenne et al. 
1999). Thus, both insulin and C-peptide are secreted in equimolar amounts (Rubenstein et 
al. 1969). C-peptide has a lower clearance rate than plasma insulin due to having fewer, less 
variable clearance routes (Rubenstein et al. 1969).  
 
In particular, the fact that C-peptide is only cleared by the kidney and not degraded in the 
liver or tissues, means that it can provide valuable information of endogenous insulin 
secretion via C-peptide models. Thus, by exploiting particular mathematical models of 
insulin kinetics, glucose-insulin dynamics and C-peptide kinetics, models can be used to 
provide a direct estimate of pancreatic β-cell insulin secretion and also of hepatic insulin 
extraction (Mari et al. 2002; Pacini & Mari 2003; Polonsky et al. 1986; Watanabe et al. 
1989).  
66 
 
 
Figure 6.2: Schematic representation of human proinsulin. (Figure taken from 
cebix.com/index.php/science/c-peptide-biology). 
 
The DISST provides quantitative measures of a participant-specific SI value and UN profile 
(Lotz 2007; Lotz et al. 2010; McAuley et al. 2011; McAuley et al. 2007). The physiological 
model used in the DISST is illustrated in Figure 6.3. The DISST SI value is highly correlated to 
the EIC (R = 0.82), and the test can contrast UN characteristics across patient groups with 
different levels of IR (McAuley et al. 2011). The DISST uses the endogenous insulin secretion 
estimation model defined by Eaton et al. (Eaton et al. 1980) and the deconvolution 
approach validated by Van Cauter et al. (Van Cauter et al. 1992), which is widely used in the 
field.  
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Figure 6.3: The physiological model of DISST. Adapted from (Docherty et al. 2009). 
 
The DISST model describes the UN profile from the deconvolution of C-peptide 
concentration (Lotz et al. 2010; McAuley et al. 2011): 
 
?̇? = −(𝑘1 + 𝑘3)𝐶 + 𝑘2𝑌 +
𝑈𝑁
𝑉𝑝
 (6.1) 
?̇? = −𝑘2𝑌 + 𝑘1𝐶 (6.2) 
 
where C and Y are the plasma and interstitial C-peptide concentrations [pmol·L-1] 
respectively; k1, k2 and k3 are the C-peptide transport rate constants [min
-1]; UN is the 
endogenous insulin secretion [mU·min-1] with a conversion factor between pmol and mU of 
6.94 pmol·mU-1 and Vp is the volume of plasma distribution [L]. 
 
Table 6.1 shows the derivation of the rate constants of k1, k2 and k3 and Vp that are defined 
a-priori based anatomical functions, as proposed by Van Cauter et al. (Van Cauter et al. 
1992). 
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Table 6.1: A-priori identification of C-peptide kinetics parameters. 
 
Steps: Normal Obese T2D 
1. Short half-life (t1/2-short) [min] 4.95 4.55 4.52 
2. Fraction (F) 0.76 0.78 0.78 
3. Long half-life (t1/2-long) [min] 𝑡1/2 − 𝑙𝑜𝑛𝑔 = 0.14 × 𝑎𝑔𝑒[𝑦𝑒𝑎𝑟] + 29.2 
4. C-peptide transport rates constants 
(k1, k2 and k3) 
𝑘2 = 𝐹 × (𝑏 − 𝑎) + 𝑎 
𝑘3 =
𝑎𝑏
𝑘2
 
𝑘1 = 𝑎 + 𝑏 − 𝑘2 − 𝑘3 
where 𝑎 =
𝑙𝑜𝑔10(2)
𝑡1/2−𝑠ℎ𝑜𝑟𝑡
 and 𝑏 =
𝑙𝑜𝑔10(2)
𝑡1/2−𝑙𝑜𝑛𝑔
 
5. Plasma distribution volume (Vp) If male: 𝑉𝑝 = 1.11 × 𝐵𝑆𝐴 + 0.64 
If female: 𝑉𝑝 = 1.11 × 𝐵𝑆𝐴 + 2.04 
where body surface area (BSA) is defined as: 
𝐵𝑆𝐴 = √
𝑤𝑒𝑖𝑔ℎ𝑡 [𝑘𝑔] × ℎ𝑒𝑖𝑔ℎ𝑡 [𝑚]
36
2
 
 
The DISST uses the integral-based estimation method to identify UN (Hann et al. 2005). 
Initially, the interstitial C-peptide concentration is determined using the analytical solution 
of Equation 6.2 and a linear interpolation between the measured C-peptide data: 
 
𝑌𝑡 = 𝑘1∫ 𝐶𝑖𝑛𝑡𝑒𝑟𝑝𝑒
−𝑘2(𝑡−𝜏)𝑑𝜏
𝑡
0
 (6.3) 
 
where Cinterp represents the linear interpolated of measured C-peptide values. 
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Later information of Y is incorporated into the integral of Equation 6.1: 
 
∫ ?̇?𝑑𝑡
𝑡1
𝑡0
= −(𝑘1 + 𝑘3)∫ 𝐶𝑑𝑡
𝑡1
𝑡0
+ 𝑘2∫ 𝑌𝑡𝑑𝑡
𝑡1
𝑡0
+∫
𝑈𝑁
𝑉𝑝
𝑑𝑡
𝑡1
𝑡0
 (6.4) 
 
Rearranging known parameters yields: 
 
𝑈𝑁(𝑡1) − 𝑈𝑁(𝑡0)
𝑉𝑝
= 𝐶𝑡1 − 𝐶𝑡0 + (𝑘1 + 𝑘3)∫ 𝐶𝑑𝑡
𝑡1
𝑡0
− 𝑘2∫ 𝑌𝑡𝑑𝑡
𝑡1
𝑡0
 (6.5) 
 
Then, UN was defined using Equation 6.5 at a 1-minute resolution between t=0 and t=end, 
by interpolating between more sparsely measured C-peptide points. 
 
 
Figure 6.4: Measured C-peptide concentration and UN profile identified by DISST model. 
 
Figure 6.4 shows that the estimated participant-specific UN profile from deconvoluted C-
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secretion of insulin. In specific cohorts it can then be used to gain insight into the 
pathophysiology of type 2 diabetes.   
 
6.3 UN model 
 
Normally, insulin is secreted by the pancreatic β-cells in response to sudden or gradual 
increases in blood glucose level. The amount of insulin secreted is dependent on the glucose 
level that needs to be lowered to a normal range value of 4 – 5.6 mmol·L-1. Although, there 
is no gold standard in identifying insulin secretion, the insulin secretion identification 
method validated by Van Cauter et al. (Van Cauter et al. 1992) has been widely used by 
many leading insulin sensitivity research groups (Bock et al. 2006; Ferrannini & Mari 2004; 
Jones et al. 1997; Mari 1998). However, this model does not account for the 
pharmacodynamic reaction on the β-cells to glucose.  
 
Secreted insulin can be quantified by 3 metrics: 1) basal endogenous insulin production (UB); 
2) first phase insulin production (U1); and 3) second phase insulin production (U2) (Lotz et al. 
2010; McAuley et al. 2011). UB is defined as the insulin required by an individual to maintain 
a constant fasting glucose measurement. U1 quantifies the dependence of insulin secretion 
on the positive rate of change of glucose concentration. Finally, in contrast to U1, U2 is 
quantifies the UN reaction to the glucose concentration over the basal glucose concentration 
at steady state. 
 
In modelling terms, the regulation of blood glucose by insulin secretion is controlled by a 
physiological closed-loop feedback-control system (Cherrington 1999). Hence, a nonlinear 
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PD model is proposed to identify the UN profile based on blood glucose behaviour. The 
proposed PD control UN model estimates the endogenous insulin secretion as a function of 
increasing glucose (derivative control, 𝜙𝐷) and glucose above basal (proportional control, 
𝜙𝑃): 
 
𝑈𝑁 = 𝑈𝐵 +𝜙𝑃(𝐺 − 𝐺𝐵) + 𝜙𝐷〈?̇?〉 (6.6) 
 
where UN is the modelled endogenous insulin secretion [mU·min
-1]; UB is basal insulin 
[mU·min-1]; G and GB is glucose and basal glucose concentration, respectively [mmol·L
-1]; 𝜙P 
and 𝜙D are the proportional, and derivative gains (mU·L·mmol
-1·min-1 and mU·L·mmol-1, 
respectively). Finally, it is important to note that 〈?̇?〉 indicates the negative rate of change in 
glucose is equal to zero, adding a nonlinear component that is physiologically relevant. 
 
Figure 6.5: Measured glucose concentration and UN profile identified from the PD UN model.  
 
Figure 6.5 shows the example of a UN profile identified from PD UN model. The proposed UN 
model directly links insulin secretion to glucose concentration. The derivative gain (𝜙D), 
determines the first phase (U1) of UN as a function of positive glucose gradient. Identifying 
the first phase insulin secretion is crucial as prior studies have shown that loss of first phase 
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insulin secretion is an independent predictor of T2D (Bunt et al. 2007; Del Prato & Tiengo 
2001; Pratley & Weyer 2001; Vranic et al. 1971; Weyer et al. 1999). The proportional gain 
(𝜙P) determines the second phase (U2) of UN and is thus, an important characteristic in the 
prediabetic state (McAuley et al. 2011; Pories & Dohm 2012).  
 
A similar control approach has been applied previously by Cobelli et al. and Ferrannini et al. 
(Breda et al. 2001; Dalla Man et al. 2010; Mari et al. 2002; Toffolo et al. 2001). It has also 
been used by Doran et al but with fixed PD gains (Chase et al. 2003). However, the proposed 
PD UN model offers model simplicity compared to previous models. The PD UN model allows 
a direct interpretation of physiological pattern of β-cell functions to glucose excursions in a 
simple, readily identifiable model. A rise in glucose level can be easily captured by the 
derivative gain whereas the proportional gain provide valuable information of UN in 
suppressing the glucose level to a normal, healthy level.  
 
6.4 Summary 
 
The proposed UN model is based on the physiological closed-loop control of insulin secretion 
in response to increasing glucose (derivative control, 
D ) and glucose above basal 
(proportional control, 
P ). By defining the model-based UN profiles as dependent on glucose 
levels, the modelling approach is more physiologically representative. Such a model might 
be particularly advantageous where samples were infrequent and deconvolution could not 
provide good resolution, by providing a structured continuous approximation to fit available 
data.  
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Chapter 7. Development of a proportional-derivative 
control model for the endogenous insulin secretion 
response to glucose 
 
This chapter presents a simple PD control model to define insulin secretion as a function of 
increasing glucose rate, derivative control, 𝜙𝐷, and glucose level above basal, proportional 
control, 𝜙𝑃.  
 
7.1 Introduction 
 
Insulin is secreted by pancreatic β cells to maintain normoglycemia. Impaired UN contributes 
to metabolic disorders, such as glucose intolerance or hyperglycemia. Hyperglycemia, if left 
untreated, ultimately leads to T2D. Understanding UN secretion characteristics is thus a 
critical aspect of characterizing this metabolic disorder (Ferrannini et al. 2005; Pacini & Mari 
2003).  
 
Assessing insulin secretion through mathematical modelling received considerable attention 
during the 1970s (Bergman & Urquhart 1971; Cerasi et al. 1974; Grodsky 1972). Unlike 
insulin sensitivity (SI) (Defronzo et al. 1979), there is no gold standard for the measurement 
of β cell function or UN. However, modelling insulin secretion as a function of peripheral C-
peptide levels by mathematical deconvolution is a widespread approach (Eaton et al. 1980; 
Van Cauter et al. 1992). This method proves more accurate than direct measurement of 
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insulin levels. In particular, insulin and C-peptide are co-secreted at equimolar rates from β 
cells (Rubenstein et al. 1969). However, the rate of insulin clearance is more variable than 
the rate of C-peptide clearance due to its greater number and variability of clearance routes.  
 
Relationships between insulin sensitivity and insulin secretion have been defined by a 
number of previous studies (e.g. (Bergman et al. 2002a; Bergman et al. 1981; Cobelli et al. 
2007; Cretti et al. 2001; Docherty et al.)). The IVGTT with minimal model has been the most 
frequently used model-based approach (Breda & Cobelli 2001; Toffolo et al. 1999). 
However, the minimal model is known to produce ambiguous SI values and erratic 
correlation with the gold standard of SI measurement, EIC (Pillonetto et al. 2002; Saad et al. 
1994), particularly for those with low SI (higher IR) (Pillonetto et al. 2002; Quon et al. 1994). 
The DISST provides a model-based SI metric that is highly correlated to the ISI metric from 
the EIC with R=0.82 (McAuley et al. 2011). The DISST also provides quantitative measures of 
UN via deconvolution of C-peptide data (Lotz et al. 2010), yielding significant added 
diagnostic insight. 
 
The physiological model used to evaluate DISST test data typically uses a deconvolution of 
measured C-peptide data to generate a participant specific UN profile.  However, it is known 
that the body uses closed-loop, feedback-control to set the rate of insulin secretion in 
response to glucose and insulin concentrations (Cherrington 1999). Hence, this chapter 
discusses a simple PD control model that defines insulin secretion as a function of rate of 
change of glucose, derivative control, and glucose level above basal, proportional control.  
Understanding the discriminatory ability of these UN gains relative to metabolic status may 
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enable greater insight into the etiology of type 2 diabetes and the metabolic syndrome than 
deconvolved UN secretion rates alone. 
 
7.2 Methods 
7.2.1 Participants and Data 
 
A total of 94 female participants were recruited from the Otago region of New Zealand to 
take part in a 10-week dietary intervention trial. Full trial details are available in Te Morenga 
et al (2010). Inclusion criteria required a body mass index (BMI) greater than 25, or BMI > 23 
and a family history of T2D, or ethnic disposition toward T2D. Participants were excluded if 
they had a major illness, including established diabetes, at the time of testing. In total, 68 
participants provided 204 full test DISST data sets at week 0, week 4 and week 10 of the 
intervention. All participants had their age and BMI recorded (median [IQR]; 42.5 [34.5, 
50.5] and 32.34 [27.92, 36.94], respectively). 
 
7.2.2 Clinical procedure 
 
Participants reported in the morning after an overnight fast. Each participant had a cannula 
inserted in the ante-cubital fossa, a vein in inner elbow, for blood sampling and 
administration of glucose and insulin boluses.  Blood samples were drawn at t=0, 5, 10, 15, 
20, 25, 30, 35, 40 and 50 minutes.  A 10g IV glucose bolus (50% dextrose and 50% normal 
saline) was administered intravenously at t=6 minutes. A 1U IV insulin bolus was 
administered intravenously at t=16 minutes. Blood samples were assayed for plasma 
glucose (Enzymatic glucose hexokinase assay, Abbot Labs, Illinois USA), insulin and C-
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peptide concentration (ELISA Immunoassay, Roche, Mannheim, Germany). All experimental 
procedures were approved by the University of Otago Human Ethics Committee. 
 
7.2.3 Physiological models 
7.2.3.1 DISST model 
 
The DISST provides quantitative measures of both SI and the UN profile (Lotz et al. 2010; 
McAuley et al. 2011; McAuley et al. 2007), and is similar to the insulin modified IVGTT, 
which uses alternative measurement and dosing, as well as a typical modelling approach 
(Bergman et al. 1979a; Ward et al. 2001). The DISST model identifies the UN profile via the 
deconvolution of C-peptide assays (Van Cauter et al. 1992). A full detailed description of the 
DISST model was well discussed in Chapter 3, Section 3.2. 
 
7.2.3.2 Proportional-derivative (PD) endogenous insulin secretion (UN) model 
 
The body uses closed-loop, feedback-control to set the rate of endogenous insulin secretion 
in response to glucose and insulin concentrations to maintain glucose homeostasis 
(Cherrington 1999). The proposed PD controller defines a patient-specific UN profile as a 
function of the rate of change of glucose, derivative control, 𝜙𝐷, and glucose level above 
basal, proportional control, ϕP. The proposed PD control model is well defined in Chapter 6, 
Section 6.3. 
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UB is derived from Equations 3.1 and 3.2 (in Chapter 3, Section 3.2), assuming a steady state 
at t = 0 minutes: 
 
𝑈𝐵 = 𝑘3𝐶0𝑉𝑝 (7.1) 
 
where 𝐶0 denotes the C-peptide measured at 𝑡 = 0. 
 
7.2.4 Parameter identification 
 
Most a-priori parameters are quantified as functions of the participant anatomical 
characteristics (weight, height, sex, age) defined by Van Cauter et al. (Van Cauter et al. 
1992). The DISST methodology typically sets pgu as a constant equal to 0.004 min
-1 (Lotz et 
al. 2010). 
 
A 7 parameter identification approach adapting the Gauss Newton method is developed to 
identify the participant-specific parameters of GB, SI, VG, 𝜙P, 𝜙D, nL and xL from the 
measured data. The function is defined: 
 
𝐱𝑖+1 = 𝐱𝑖 − (𝐉
𝐓𝐉)−1𝐉𝐓𝛙 (7.2) 
 
where 𝐱𝑖 = [𝐺𝐵𝑖 , 𝑆𝐼𝑖, 𝑉𝐺𝑖 , 𝜙𝐷𝑖 , 𝜙𝑃𝑖 , 𝑛𝐿𝑖 , 𝑥𝐿𝑖] is the parameter vector and 𝑖 is the iteration 
number. The Jacobian matrix (J) and the residual matrix (ψ) are defined: 
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𝐉(𝐱𝑖) =     
[
 
 
 
 
 
 
 
𝛿𝜓1
𝛿𝐺𝐵
𝛿𝜓1
𝛿𝑆𝐼
⋯
𝛿𝜓1
𝛿𝑥𝐿
𝛿𝜓2
𝛿𝐺𝐵
𝛿𝜓2
𝛿𝑆𝐼
⋯
𝛿𝜓2
𝛿𝑥𝐿
⋮ ⋮ ⋱ ⋮
𝛿𝜓𝑛
𝛿𝐺𝐵
𝛿𝜓𝑛
𝛿𝑆𝐼
⋯
𝛿𝜓𝑛
𝛿𝑥𝐿 ]
 
 
 
 
 
 
 
 
 
𝛙(𝐱𝑖) =
[
 
 
 
 
 
 
 
 
 
 
(𝐺(𝐱𝑖, 𝑡1) − 𝐺𝑀,1) 𝐺𝑀̅̅ ̅̅⁄
⋮
(𝐺(𝐱𝑖, 𝑡𝑛) − 𝐺𝑀,𝑛) 𝐺𝑀̅̅ ̅̅⁄
(𝐶(𝐱𝑖, 𝑡1) − 𝐶𝑀,1) 𝐶𝑀̅̅ ̅̅⁄
⋮
(𝐶(𝐱𝑖, 𝑡𝑛) − 𝐶𝑀,𝑛) 𝐶𝑀̅̅ ̅̅⁄
(𝐼(𝐱𝑖, 𝑡1) − 𝐼𝑀,1) 𝐼?̅̅̅?⁄
⋮
(𝐼(𝐱𝑖, 𝑡𝑛) − 𝐼𝑀,𝑛) 𝐼?̅̅̅?⁄ ]
 
 
 
 
 
 
 
 
 
 
 
(7.3) 
 
where 𝐼(𝐱𝑖, 𝑡𝑛), 𝐺(𝐱𝑖, 𝑡𝑛) and 𝐶(𝐱𝑖, 𝑡𝑛) are the simulated values at t = tn given 𝐱𝑖; 𝐼𝑀,𝑛, 𝐺𝑀.𝑛 
and 𝐶𝑀,𝑛 are the measured values at t = tn; n is the number of measured samples; and 𝐼?̅̅̅?, 
𝐺𝑀̅̅ ̅̅  and 𝐶𝑀̅̅ ̅̅  are the mean measured values of these species. 
 
To avoid model misidentification issues, insulin samples taken within 10 minutes of insulin 
administration and glucose samples taken within 10 minutes of glucose injection in the 
DISST protocol were ignored in the model identification process to minimize errors 
introduced by the confounding effects of intravascular mixing (Caumo et al. 1999; Edsberg 
et al. 1987; Lotz 2007). The value of VG was limited to physiological bounds to reduce the 
effect that incomplete mixing might have during the parameter identification process. In 
particular, VG is constrained within the range of 0.12Bw to 0.25Bw where Bw is measured in 
kg and the coefficients have units of L·kg-1 (Defronzo et al. 1979; Ferrannini & Mari 1998; 
Lotz 2007; Lotz et al. 2010). 
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7.3 Statistical analysis 
 
Model residuals and interpretation of population trends were used to assess the 
performance of the PD based UN model by comparing fitted C-peptide versus measured C-
peptide values. The residual error of C-peptide determines the performance of the UN 
profile of this PD model against the de-convoluted UN profile, as defined by Equations 7.4 – 
7.6. 
 
Mean Residual error of C-peptide (μ) is defined: 
𝜇(𝑡) =
1
𝑛
∑
𝐶𝑓𝑖𝑡𝑡𝑒𝑑(𝑡) − 𝐶𝑚𝑒𝑎𝑠𝑢𝑟𝑒𝑑(𝑡)
𝐶𝑚𝑒𝑎𝑠𝑢𝑟𝑒𝑑(𝑡)
 
(7.4) 
 
Standard error of C-peptide (SE) is defined: 
𝑆𝐸(𝑡) =
𝑆𝐷(𝑡)
√𝑛
 
(7.5) 
 
where standard deviation (SD) is defined as: 
𝑆𝐷 = √
∑(𝐶𝑓𝑖𝑡𝑡𝑒𝑑(𝑡) − 𝜇(𝑡))
2
𝑛
 
(7.6) 
 
where blood samples were collected at t = 0, 5, 10, 15, 20, 25, 30, 35, 40 and 50 min for the 
measurement of C-peptide and n is the number of tests conducted amongst 68 participants. 
 
Correlations were used to describe the relationship between ratio of 
𝜙𝐷
𝜙𝑃
 and SI, as well as 
𝜙D against 𝜙P. All analysis was undertaken using MATLAB (R2013b, Mathworks, Inc., Natick, 
MA, USA). 
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7.4 Results 
 
Figure 7.1 shows the simulated versus measured plasma insulin, glucose, C-peptide and UN 
profiles from one typical participant. Note again that the insulin and glucose samples taken 
within 10 minutes of bolus injection were ignored due to unmodelled mixing effects. In 
general, using the DISST model with a PD derived UN model and a Gauss Newton 
identification method shows that the simulated data fits well against the measured data.  
 
 
 
Figure 7.1: Simulated (solid blue line) and measured (red ‘+’ symbol) of; (A) plasma insulin, 
(B) glucose, (C) C-peptide for a typical participant response to the DISST model, and (D) 
Endogenous insulin secretion profile identified from the PD modelled UN model (solid blue 
line) and from deconvoluted C-peptide measurement (dashed green). 
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Figure 7.2 shows the residual error between the measured C-peptide data and the response 
modelled by PD UN model on Equation 7.1 for all 204 tests. Figure 7.3 shows the 
dependence of the ratio  
𝜙𝐷
𝜙𝑃
 to SI with R = 0.33. Figure 7.4 shows the distribution of 𝜙𝑃 as a 
function of 𝜙𝐷 with weak correlation of R = 0.32. Although the correlation was weak, it 
elucidates greater information on β-cell functionality in maintaining glucose level in 
bloodstream. 
 
 
 
Figure 7.2: Residual error (mean and standard error, 𝑆𝐸 =
𝑆𝐷
√𝑁
) between the measured C-
peptide data and the response modelled by PD UN model. 
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Figure 7.3: Ratio of  
𝜙𝐷
𝜙𝑃
 as a function of SI, with line defined for R = 0.33. 
 
 
Figure 7.4: Distribution of 𝜙D against 𝜙P for all tests. 
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7.5 Discussion 
 
The DISST validation study used deconvolution of measured C-peptide data to determine 
participant-specific UN profiles (Lotz et al. 2010). It clearly showed that similar SI values did 
not necessarily have similar UN profiles. Thus, it was able to differentiate clearly different 
states in the progressive of T2D. 
 
However, regulation of blood glucose by endogenous insulin is effectively a closed-loop 
feedback-control system (Cherrington 1999). Secretion responds to level and rate of change 
of glucose. Hence, a PD model is proposed that mimics this behaviour to identify the UN 
profile.  
 
Studies have also shown that the insulin secretory response to glucose is multiphasic in 
nature (Cerasi 1967; Curry et al. 1968). The first phase of insulin is secreted immediately in 
response to sudden increases in the glucose level. Hence, it causes a rapid elevation of 
plasma insulin with at peak value achieved within five minutes (Lerner & Porte 1971). The 
second phase of insulin is slowly and gradually released in response to sustained elevation 
in plasma glucose (Lerner & Porte 1971). 
 
The PD UN model developed here defines UN based on three physiological stages: 1) UB is 
the basal endogenous insulin production rate; 2) U1, the magnitude of the first phase 
response to glucose appearance; and 3) U2 is the second phase response to glucose. U1 is 
thus, mathematically defined as linearly dependent on the positive rate of change of glucose 
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concentration. Whereas, the magnitude of the U2 is defined as proportional function over 
the basal glucose concentration at steady state (Docherty 2011). 
 
Figure 7.1 shows the plasma insulin, glucose, C-peptide and UN profile of simulated and 
measured data from one participant. In particular, it elucidates the difference between 
identified UN from the PD control and the for less smooth and less realistic deconvoluted UN 
profile. It also shows that the general trends of UN from the PD control UN model were in 
accordance with the deconvoluted UN profile providing a measure of validation. This 
behaviour indicates that the PD UN model is capable of capturing the first and second 
phases of insulin secretion responses to the glucose bolus encountered in dynamic tests. 
Moreover, the proposed model provides a direct physiological link between glucose 
concentration and resultant insulin secretion, which is physiologically accurate and provides 
a means to model this behaviour with limited data. Hence, the main benefit of the proposed 
model may be found when a lack of resolution in the C-peptide samples reduces the 
accuracy of the resulting deconvolved profile. 
 
Figure 7.2 shows the residual error between measured C-peptide data and the response 
modelled by PD UN model and Equation 7.1. It can be said that higher residual error at the 
forth C-peptide assay may be due to timing as this sample attempts to capture peak first 
phase response in the DISST before full mixing may have occurred. However, the residual 
error value tended to stay within the 10% of the measured data.  
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Figure 7.3 shows the distribution of 
𝜙𝐷
𝜙𝑃
 against the SI value. Although the correlation of 
between 
𝜙𝐷
𝜙𝑃
 and SI was weak (R = 0.33), it elucidates a trend between SI and  
𝜙𝐷
𝜙𝑃
. The trend 
indicates that those with low ratios typically had lower insulin sensitivity than the general 
cohort. In general, as the ratio of 
𝜙𝐷
𝜙𝑃
 decreases, SI value will decrease. Hypothetically, IR 
participants typically have limited first phase and high basal secretion, requiring a different 
set of 𝜙𝑃 and 𝜙𝐷 values than a healthy person with high first phase and low basal. 
 
Clinically, an increased basal insulin secretion and blunted first phase response indicates an 
early stage in the progression of impaired glucose tolerance (Lotz et al. 2010; McAuley et al. 
2011). Further, an individual that has established T2D can have low basal insulin and 
virtually no first phase secretion. Equally, a healthy athletic person may generally also have 
low basal secretion, and high or low first phase secretion. Thus, IR participants relied more 
heavily on the second phase or proportional gain in maintaining the glucose homeostasis. 
This latter point was inferred by the diagnostic value of U2 in (McAuley et al. 2011), and 
matches clinical expectations (Ferrannini 1997). Higher second phase secretion is also well 
captured by this PD modelling approach. 
 
Figure 7.4 shows the distribution value of 𝜙𝐷 and 𝜙𝑃. It can be seen that 𝜙𝐷 has a greater 
value than 𝜙𝑃. 𝜙𝐷 was typically an order of magnitude (×20) 𝜙𝑃. Although both gains play 
an important role in glucose homeostasis, it is thought that the U1 provides greater 
influences in suppressing the sudden elevated plasma glucose level back to a normal level. 
Studies have shown that the loss in U1 is a strong predictor of type 2 diabetes (Bunt et al. 
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2007; Del Prato & Tiengo 2001; Pratley & Weyer 2001; Vranic et al. 1971; Weyer et al. 
1999). 
 
This study was undertaken in a cohort of adult female participants that were considered ‘at-
risk’ of type 2 diabetes and related metabolic disorders. Hence, the outcomes of this study 
may be isolated to cohorts of this type. However, it may be reasonably assumed that gender 
does not play a significant role in the modulation of insulin secretion as a function of glucose 
excursions in adults, and no prior literature in a large field suggests otherwise. Furthermore, 
this at-risk cohort is a cohort of greatest clinical interest to the mitigation of glycaemic and 
other metabolic disorders. However, further confirmation must be undertaken in various 
other cohorts. 
 
7.6 Summary 
 
This chapter presents a thorough analysis of a simple, but effective PD control model of 
insulin secretion. The proposed model links insulin secretion to glucose concentration and is 
able to deliver a good compromise between model simplicity and accuracy. Although the 
proposed model requires further validation, it is likely to be useful for analysis of the 
pathogenesis of T2D as it captures the physiological determinants of patient-specific UN 
profile. 
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Chapter 8. The efficacy of the PD UN model in 
identifying the condition stage of a participant   
 
This chapter discuss the efficacy of the proposed PD UN model in identifying the condition 
stage of each participant based on the UN profile derived from PD UN model. 
 
8.1 Introduction 
 
Deconvolution of C-peptide concentration measurements is regarded as the best 
identification method in quantifying the UN profiles, and is used by most studies (e.g. (Eaton 
et al. 1980; Polonsky et al. 1986; Van Cauter et al. 1992)). This method is assumed to be 
accurate due to the fact that insulin and C-peptide are co-secreted in an equimolar fashion 
from the pancreatic β cells (Rubenstein et al. 1969). Unlike C-peptide, acquiring plasma 
insulin measurements to precisely predict UN will lead to false information as insulin 
undergoes a substantial, subject-specific first pass hepatic extraction before reaching the 
peripheral circulation (Hovorka & Jones 1994; Polonsky & Rubenstein 1986). In addition, 
insulin is cleared subsequently by the liver, kidney and peripheral uptake, all of which can be 
variable and hard to quantify. In contrast, C-peptide is only cleared by the kidney, which is a 
reasonably low variability pathway. Thus, C-peptide data is the best, most robust means of 
estimating endogenous insulin secretion. 
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Although the use of  C-peptide has proven a better means of estimating UN (Pacini & Mari 
2003), the need for C-peptide measurement during study is time-consuming and expensive 
(Lin et al. 2010). The added cost can significantly reduce the economic viability of effective 
diabetes screening tests (Docherty et al. 2010; Docherty et al. 2011b). Hence, there remains 
significant scope and impact in better identifying a UN profile without the use of many C-
peptide measurements. 
  
The PD control model discussed in Chapter 7 provides the capability of using the PD model 
to link the patient-specific UN profile to glucose excursions. Physiologically, the amount of 
insulin to be secreted is determined most prominently by glucose level and the change in 
glucose level (gradient). The 𝜙𝐷 and 𝜙𝑃 identified by a PD UN model is thus able to capture 
the physiological characteristics of first and second phase of insulin secretion, respectively.  
 
Studies have shown that the insulin secreted by pancreatic β-cells is secreted in a biphasic, if 
not multiphasic, pattern (Cerasi 1967; Cerasi & Luft 1967; Curry et al. 1968). The UN profile 
in response to glucose challenge or appearance is typically quantified into 2 phases; 1) first 
phase secretion and 2) second phase secretion. The first phase occurs rapidly due to a 
sudden change in glucose level after glucose stimulation and only lasts for few minutes 
(Curry et al. 1968). Unlike first phase, the second phase secretion lasts longer, as it is 
gradually released by the pancreatic β-cells to reduce the remaining elevated glucose level 
to a safe, normal level (Curry et al. 1968). Figure 8.1 shows a schematic UN with first and 
second phase secretion.  
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Figure 8.1: Illustration of insulin secretion from pancreatic β-cell. UB is defined as basal 
insulin, U1 is first phase and U2 is the second phase of insulin secretion. 
 
The relationship between the characteristics of first and second phase UN with T2D is well 
founded by prior studies (Bunt et al. 2007; Del Prato & Tiengo 2001; Pratley & Weyer 2001; 
Weyer et al. 1999). It is thought that the loss of first phase secretion and reduced second 
phase secretion define the UN characteristics of T2D (Cerasi & Luft 1967; Davis et al. 1993). 
Since the PD UN model captures the pancreatic response to glucose, associating 𝜙𝐷 and 𝜙𝑃 
to the first and second phase secretion provides an insight gain towards understanding the 
pathogenesis of type 2 diabetes. In particular, the changes in 𝜙𝐷 and 𝜙𝑃 as diabetes 
develops should illustrate these observed changes in secretion pattern. Hence, this chapter 
investigates the accuracy of this previously proposed PD control UN model in identifying and 
discriminating the UN profile for NGT and IFG participants, particularly in relation to changes 
0 5 30
Time [min]
In
s
u
li
n
 s
e
c
re
ti
o
n
 
 
U
B
U
1
U
2
90 
 
in PD model parameters between these two groups. Successful outcome would indicate the 
diagnostic potential of subject-specific 𝜙𝐷 and 𝜙𝑃 values. 
 
8.2 Methods 
 
A total of 204 full test DISST data sets, recorded from 68 female participants in a 10-week 
dietary intervention trial, were used to further analyse the efficacy of PD based UN model. 
The 𝜙𝐷 and 𝜙𝑃 values were identified in a seven parameter identification approach  
(𝑥 = [𝐺𝐵, 𝑆𝐼, 𝑉𝐺 , 𝜙𝐷 , 𝜙𝑃, 𝑛𝐿 , 𝑥𝐿]) using the Gauss Newton parameter identification method 
(Björck 1996). A full detailed description of the identification methodology was discussed in 
Chapter 7, Section 7.2. 
 
8.3 Statistical analysis 
 
In this study, the PD UN model accuracy was assessed via the produced residual matrix (ψ). 
The results of 𝜙𝑃 and 𝜙𝐷 are reported in median and interquartile range (IQR) for 3 
participant categories: All, NGT, and IFG. All analyses were undertaken using MATLAB 
(R2013b, Mathworks, Inc., Natick, MA, USA). 
 
8.4 Results 
 
Among 204 full DISST test data sets, 17 were classed as IFG based on a G0 cut-off value of 
5.56 mmol·L-1 (100 mg·dL-1) as defined by the American Diabetes Association (ADA) criteria 
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(ADA 2014). Figure 8.2 shows the distribution of 𝜙𝐷/𝜙𝑃 ratio against G0 across NGT and IFG 
group sets of data. It also shows that the median value of 𝜙𝐷/𝜙𝑃 for NGT is higher than for 
IFG with 19.11 min and 2.76 min, respectively. In addition, the distribution data of the ratio 
of 𝜙𝐷/𝜙𝑃 versus G0 are group into A, B and C, and are qualitatively cross-referenced with 
the insulin resistance and first phase secretion plot from Ferrannini et. al. (Ferrannini 1997). 
 
Figure 8.3 shows the gain distribution of 𝜙𝐷 versus 𝜙𝑃 across both groups. It shows that 𝜙𝐷 
values are greater value than 𝜙𝑃. In addition, the dotted lines of 𝜙𝐷/𝜙𝑃 = 5, 10, and 100 
show the distribution of both gains with relations to the state of participants as portrayed in 
Figure 8.2. Furthermore, it shows that as the ratio decreases, the profile of the participant 
moves from NGT to IFG, as expected and seen in Figure 8.2. A full statistical summary of 
both gains are presented in Table 8.1. It can be seen that while the median of 𝜙𝑃 remains 
equal across both groups of participant, 𝜙𝐷 remains significantly different where 𝜙𝐷NGT ≈ 
4 × 𝜙𝐷 IFG, (p < 0.0001). Thus, as expected, 𝜙𝐷 and first phase response is reduced 
significantly in IFG subjects, which is a pre-cursor to T2D. 
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Figure 8.2: Distribution of 𝜙𝐷/𝜙𝑃 against G0 where X = 19.11 min and Y = 2.79 min. Insert 
picture is the insulin resistance (as measured by glucose disposal) and first phase insulin 
secretion plot versus 2 hour glucose levels in NGT, IGT and T2D (adapted from (Ferrannini 
1997)). 
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Figure 8.3: Distribution of 𝜙𝐷  over 𝜙𝑃 during the intervention study. The 𝜙𝐷/𝜙𝑃 = 5, 10, and 
100 dotted lines are shown for context. 
 
Table 8.1: Summary statistics of derivative (𝝓D) and proportional (𝝓P) gains. 
 
  
Median 
[IQR] 
Group Total 
𝜙𝑃 
[mU·L·mmol-1·min-1] 
𝜙𝐷 
[mU·L·mmol-1] 
𝜙𝐷
𝜙𝑃
 
[min] 
NGT 187 
69.58 
[43.06, 96.41] 
1283.37 
[879.35, 1848.09] 
19.11 
[13.19, 27.61] 
IFG 17 
69.47 
[49.51, 100.07] 
302.55 
[25.72, 756.46] 
2.79 
[0.15, 13.25] 
 
 
Figure 8.4 shows the PD model simulated versus measured plasma glucose and UN profiles 
from 3 different participants. The 3 participants have high, average and low SI values, and 
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thus cover the range of participants. Note again that the glucose samples taken within 10 
minutes of bolus injection were ignored due to unmodelled mixing effects. It can be seen 
that as a participant’s G0 rises above the 5.56 mmol·L
-1 diagnostic threshold for IFG, the 
value of 𝜙𝐷 drops and becomes approximately equal to 𝜙𝑃. 
 
Figure 8.5 depicts a relationship between the ratio of 𝜙𝐷/𝜙𝑃 against BMI value, which is 
another risk factor for IFG and T2D (Kahn et al. 2006). In particular, 16 out of 17 IFG 
participants are obese and have a lower ratio of 𝜙𝐷/𝜙𝑃. Thus, as the BMI of the participant 
increases, there is a general trend for their profile tends to shift from NGT to IFG. This was 
expected from clinical literature (Kahn et al. 2006).  
 
In addition, Figure 8.6 shows the correlation between each of the gains versus the BMI value 
for both groups. It can be seen that, at BMI > 30, which defines obese (WHO 2000), 𝜙𝐷 for 
the IFG group is significantly lower than for the NGT with median value of each group equals 
to 283 mU·L·mmol-1·min-1 and 1568 mU·L·mmol-1 (p < 0.0001) respectively. Additionally, the 
𝜙𝑃 value for IFG subjects remains closer to the NGT value with median values equal to 70 
mU·L·mmol-1·min-1 and 85 mU·L·mmol-1 (p = 0.3601) respectively. 
 
Figure 8.7 shows the distribution of the ratio of 𝜙𝐷/𝜙𝑃 against the participant’s age. 
Although, NGT participants cover most of the range from 20 to 65 years old, the IFG 
participants are aged 35 to 61 years old. However, Figure 8.7 shows that there is no clear 
relationship between age and the ratio of 𝜙𝐷/𝜙𝑃, which is expected given similar ages and 
different insulin resistance and diabetes status. Thus, the correlations hold with expected 
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and reported clinical observations, and, equally importantly, are poor where no prior clinical 
observation has been found. 
  
 
Figure 8.4: Relationship between plasma glucose concentration and UN profile from 3 
different participant response to the DISST and PD UN model. 
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Figure 8.5: Distribution of the ratio of 𝜙𝐷/𝜙𝑃against BMI value for all 204 tests. 
 
Figure 8.6: Distribution of each derivative and proportional gain versus BMI value. 
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Figure 8.7: Distribution of 𝜙𝐷/𝜙𝑃 against participant’s age. 
 
 
8.5 Discussion 
 
Like most secretion studies (Eaton et al. 1980; Polonsky et al. 1986; Van Cauter et al. 1992), 
the DISST model-based approach was developed to use deconvolution of C-peptide data to 
determine participant specific UN profiles (McAuley et al. 2011). Although, the identification 
of UN based on the deconvolution of C-peptide data is relatively accurate, due to the fact 
that insulin and C-peptide are equimolarly secreted by pancreatic β-cells, there remains 
scope to better identify UN as C-peptide measurements are often sparse. It is known that 
the regulation of blood glucose concentrations is effectively a closed-loop feedback-control 
system (Cherrington 1999). Thus, a subject-specific PD model is used that directly mimics 
this behaviour to identify a smoother more, physiologically UN profile. However, the main 
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purpose of this chapter was to further validate the PD UN model by its ability to differentiate 
NGT and IFG participants.  
 
The proposed PD UN model distinguishes the UN profile into 3 major roles; UB, first phase 
insulin secretion and second phase insulin secretion. The 𝜙𝐷 captures the first phase of UN 
(U1) based on the dependence of insulin secretion on the positive rate of change of glucose 
concentration. The 𝜙𝑃 effectively determines the second phase of UN (U2), as well as the 
basal level when there is no challenge, based on a proportional function over the basal 
glucose concentration at steady state.  
 
Figure 8.2 shows the distribution of 𝜙𝐷/𝜙𝑃 against G0 on a log scale with the ADA guideline. 
It can be seen that the NGT group has higher gain ratio compared to the IFG group (p < 
0.0001), where the median value of gain ratio was  ̴7× higher. Only 5 out of 187 NGT results 
are below the IFG median value showing clear separation. Theoretically, an individual with 
higher insulin resistance will have a limited first phase secretion, based on many clinical 
observations (Ferrannini 1997), causing a much lower 𝜙𝐷/𝜙𝑃 ratio than a healthy 
participant with a high first phase insulin secretion. Hence, this resultant difference in 
median ratios is expected. 
 
The development of T2D is a more gradual process compared to type 1 diabetes. The 
pathogenesis of T2D progresses through 3 distinct stages: 1) NGT; 2) IGT; and 3) T2D 
(Ferrannini 1997; Pories & Dohm 2012). In addition, IFG is defined by an elevation fasting 
plasma glucose between 100 to 125 mg·dL-1, while IGT, on the other hand, is defined by an 
elevated 2-h post load of OGTT plasma glucose between 140 to 199 mg·dL-1 (ADA 2014; 
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Nathan et al. 2007). Like IGT, IFG also represents as an intermediate metabolic state 
between normal glucose homeostasis and diabetes (Alberti & Zimmet 1998; Ferrannini 
1997; Nathan et al. 2007). In general, determining the value of the 𝜙𝐷 and proportional gain 
𝜙𝑃 is crucial when assessing which stage the participant belongs to. Studies have shown 
that loss of first phase insulin secretion is an independent predictor of eventual type 2 
diabetes (Bunt et al. 2007; Del Prato & Tiengo 2001; Pratley & Weyer 2001; Vranic et al. 
1971; Weyer et al. 1999). In addition, second phase insulin secretion is an important 
characteristic in the prediabetic state (McAuley et al. 2011; Pories & Dohm 2012). However, 
for early diagnosis, it is the changes in 𝜙𝐷 that appear most important, and are captured at 
intermediate stages in the patho-physiology of T2D. 
 
In addition, Figure 8.2 also shows a clear relationship between the ratio of both gains of the 
PD UN model against participant’s condition based on ADA guidelines (ADA 2014). Previous 
study has shown that changes in the first phase secretion reflects directly to the movement 
of the state of individuals from NGT to IGT, and drops drastically as it reaches diabetes 
(Ferrannini 1997). Evidently, if 𝜙𝑃 is assumed to be constant, based on the result of median 
value in Table 8.1 for both groups of participant, 𝜙𝐷 plays a critical role in deciding the ratio 
of 𝜙𝐷/𝜙𝑃. As the value of 𝜙𝐷 increases, the ratio increases until it reaches a plateau before 
it drops significantly. Furthermore, it can be seen that, the ratio of 𝜙𝐷/𝜙𝑃 at the early stage 
of IFG is almost equal to ratio for the NGT group. Prior studies show that UN did not differ 
significantly from normal individuals at early stage of IGT, but later drops abruptly as 
diabetes develops fully (Ferrannini 1997; Groop et al. 1993).   
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Figure 8.3 shows that while 𝜙𝐷 gains are scattered across a wider range from   ̴0 to 4.93×10
3 
mU·L·mmol-1, 𝜙𝑃 remains in a narrow range from 7.09 to 236.06 mU·L·mmol
-1·min-1. In 
addition, Table 8.1 shows that although 𝜙𝑃 holds similar values across both groups, 𝜙𝐷 
remains significantly different between the NGT and IFG groups (p < 0.0001). Thus, as 𝜙𝐷 
decreases, the metabolic state of the participant could be hypothesized to move from NGT 
toward IFG and the first known symptoms of diabetes. Figure 8.3 also shows the lines of 
𝜙𝐷/𝜙𝑃 ratio discriminating different participant types for the most part, as well as this 
trajectory of developing diabetes.  
 
Figure 8.4 elucidates that as a participant is diagnosed with IFG (G0 > 5.56 mmol·L
-1 (ADA 
2014)), the value of 𝜙𝐷 tends to reduce and becomes almost equal to 𝜙𝑃. However, for NGT 
participant (G0 < 5.56 mmol·L
-1), 𝜙𝐷 has a greater value than 𝜙𝑃. Hence, by judging the 
pattern of each UN profile, it can be said that when 𝜙𝐷 decreases or moves closer to 𝜙𝑃, the 
participant is losing burst secretion for first phase as IR rises (Ferrannini 1997).  
 
In addition, studies show that the intermediate metabolic state between normal and 
diabetes is more associated with decreased insulin sensitivity, rather than insulin secretion 
itself (Ferrannini 1997). The latter point is portrayed in Figure 8.4. In addition, Participants 1 
and 2 have almost similar UN profiles. However, Participant 2 is diagnosed as IFG. Hence, by 
examining the UN profile itself, without considering the fasting glucose condition, this 
Participant 2 could be interpreted as a having normal, healthy pancreatic response to the 
glucose challenge. However, the SI value shows that Participant 2 has a lower SI value, 3.45 
× 10-4 L·mU-1·min-1 compared to SI = 8.92 × 10-4 L·mU-1·min-1 for Participant 1. Although, 
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there is no agreed diagnostic SI value, prior studies have shown that lower SI values are a 
major factor of the pathogenesis of T2D (Ferrannini 1997; Ferrannini & Mari 1998). 
 
While both gains play an important role in defining the participant-specific UN profile, the 
𝜙𝐷 appears to be more important in defining the early changes in the metabolic state of the 
participant. Theoretically, if 𝜙𝑃 is fixed to a certain value, 𝜙𝐷 will vary when quantifying the 
participant-specific UN profile depending on the metabolic state of the participant. A value 
of 𝜙𝐷 ≈ 0 is predicted for participants with type 2 diabetes. Furthermore, down sampling 
measured glucose data when assessing UN characteristics over a limited period of time from 
0 to 30 min will result in significantly reduced clinical cost and clinical attention during the 
trial. With fewer samples, the outcome result would provide less effective information 
compared to a full data set. However, further validation is needed to prove both 
assumptions and to determine the degree to which the findings of this study can be 
interpolated in a down-sampling exercise to reduce test cost and intensity.  
 
Figure 8.5 shows the correlation between the 𝜙𝐷/𝜙𝑃 ratio against the BMI value for both 
NGT and IFG with R = -0.21 and R = 0.05, respectively. Although, the correlation was weak, 
the outcome elucidates the ratio of 𝜙𝐷/𝜙𝑃 for the IFG group is significantly lower than for 
NGT, particularly for obese participants. In addition, judging from Figure 8.6, particularly on 
the distribution of 𝜙𝐷 against BMI value, it can be postulated that obese participants with 
higher fasting glucose have reduced first phase secretion compared to normal, healthy 
participant, matching many clinical studies and the strong association of obesity with IFG 
and T2D. Further, studies have found that the level of first phase insulin secretion is reduced 
in individuals with higher plasma glucose than normal and essentially absent in individuals 
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with fasting hyperglycemia (Brunzell et al. 1976; Kahn et al. 1969). Thus, these results match 
clinical results. Thus, given the loss in first phase secretion for the IFG group, Figure 8.6 also 
shows that the IFG participants rely heavily on second phase secretion to restore 
normoglycemia, again matching known clinical observations.   
 
Figure 8.7 shows age brings little impact during the identification of UN profile. Although 
glucose tolerance decreases with advancing age in general, the aging process generates 
more impact on insulin sensitivity than secretion (DeFronzo 1981). Prior study also shows 
that there is a variability in associating the effects of aging on insulin secretion particularly 
with confounding factors associated with obesity and concomitant insulin resistance 
(Adelman 1989). Thus, the failure to associate age and impaired UN matches clinical results, 
and further validates the diagnostic value of the PD model parameters. 
 
While this PD control UN model requires further validation, it is likely to be useful for 
analysis of the pathogenesis of T2D as it captures the physiological determinants of 
participant-specific UN profiles. Ultimately, this model provides a direct physiological link 
between insulin secretion to glucose concentration, as well as to eventual insulin sensitivity. 
 
8.6 Summary 
 
This chapter discussed a further analysis of the proposed PD UN model adapting a Gauss 
Newton parameter identification method. The proposed model offers model simplicity as 
well as a link between insulin secretion and glucose concentration. In addition, the UN 
profile response from PD UN model provides clear information in determining the condition 
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stage of each participant, and this status is reflected and captured by the values of the PD 
model gains 𝜙𝐷 and 𝜙𝑃.  
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Chapter 9. Conclusions and future work 
 
9.1  Conclusions 
 
Type 2 diabetes mellitus (T2DM) is a metabolic disease that affects the body’s ability to 
regulate glucose levels in blood. T2DM is characterized by fasting hyperglycemia and an 
excessive rise of glucose levels in the blood above baseline following glucose or meal 
ingestion resulting from impaired insulin utilization (insulin resistance) coupled with the 
body’s inability to compensate with insulin production (insulin deficiency). Thus, 
identification of these two main factors can offer the clinical opportunities to ameliorate the 
worst symptoms of the disease. 
 
The broad relationship between insulin sensitivity and insulin secretion is well-known. 
Throughout years, studies have developed test protocols consists of mathematical 
modelling coupled with clinical analysis to identify pathogenesis of T2D through a 
quantitative assessment of insulin sensitivity and estimation of UN. The application of 
modelling to clinical research has since been slow, but the IVGTT with minimal model has 
been the most frequently used model-based approach for measuring glycemic metabolism. 
However, like most model-based assessment, IVGTT is limited to research-only application 
due to its intensity, length and complexity to perform. Furthermore, the IVGTT is generally 
known to produce ambiguous SI values and erratic correlations with the gold standard. 
Hence, this thesis develops a more comprehensive glucose-insulin pharmacokinetics and 
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pharmacodynamics model that can be assessed with high accuracy, high mathematical 
robustness from a novel low cost and duration test protocol for type 2 diabetes patients. 
 
This thesis improves two key aspects that to benefit the analysis of the pathogenesis of T2D. 
More specifically, the identification approach that accurately assesses SI values, especially 
for individuals with established T2D by redefining the role of basal glucose level and 
identifying it directly. Second, this thesis proposed a PD model that able to identify a 
smoother physiologically UN profile that mimic the behaviour of a closed-loop feedback 
control human body system when regulating the blood glucose levels, and enabling for 
more precise estimates of SI from data. Both outcomes also deliver potential real diagnostic 
and monitoring metrics, as well. 
 
With the assumption of G0 equals to GB, like most model-based assessments of SI, the SI 
value is well addressed by DISST model using a 2-parameter identification approach (x = [SI, 
VG]). However, evidence suggests that GB ≠ G0, and thus, should be treated as separate 
entities especially in individuals with established diabetes. Hence, the original DISST model, 
while appropriate for more normoglycaemic cohorts, needs to model GB as a variable for 
assessing individuals with established T2D. A 3-parameter identification approach is 
developed where GB is identified in concert with SI and VG, where (x = [GB, SI, VG]).   
 
Result in Chapter 4 showed a significant differences between the G0 and identified GB values 
in this cohort (prs and pks < 0.0001), although both values were well correlated (R = 0.70). 
This analysis has shown that GB is an important variable for modelling the glycaemic 
behaviour in T2D. This analysis suggests that the identified basal glucose is a more 
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appropriate variable for individuals with type 2 diabetes, as using the fasting glucose 
measurement as the basal set-point was shown to be a poor assumption for this cohort - 
although this requires confirmation in a larger study with a clamp as the reference.  
 
Clinically, identifying GB, SI and VG as model variables in a 3-parameter identification also 
allows greater descriptive ability of the metabolism of individuals with T2D. The assumption 
of GB = G0 effects the typical 2-parameter identification employed by DISST model and 
results by leading to potentially erroneous SI values or SI changes due an intervention, 
which could lead to ineffective interventions being seen as effective, and vice versa. Chapter 
5 showed that the SI value identified by the 3-parameter modelling approach were 
significantly lower (p<0.05) than the 2-parameter modelling approach. The findings were in-
line with expected participant physiology. Thus, the typical modelling approaches, with an 
assumption of GB = G0, can over-estimate sensitivity in this cohort by lumping GB dynamics 
into SI. Finally, the identified GB tracked well with T2D pathogenesis, offering a new 
monitoring metric that in future could augment the well known HbA1C. 
 
Modelling insulin secretion as a function of peripheral C-peptide levels by mathematical 
deconvolution has become a widespread approach. Although it remains to be the best 
method in identifying endogenous insulin due to the fact that C-peptide and insulin are co-
secreted from β-cells, these C-peptide measurements are relatively sparse, costly to obtain 
and time-consuming. Hence, while diagnostically affective, there is room for improvement 
and to reduce sampling and thus cost. 
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The proposed UN model is based on the physiological closed-loop control of insulin secretion 
in response to increasing glucose (derivative control, 
D ) and glucose above basal 
(proportional control, 
P ). By defining the model-based UN profiles as dependent on glucose 
levels, the modelling approach is more physiologically representative. Although the 
proposed model requires further validation, it is likely to be useful for analysis of the 
pathogenesis of T2D as it captures the physiological determinants of patient-specific UN 
profile. 
 
The simplicity of PD UN model provides clear relationship between the UN profile and the 
metabolic state of each participant. This metabolic status is reflected and captured by the 
values of the PD model gains 𝜙𝐷 and 𝜙𝑃. An individual with higher insulin resistance will 
have a limited first phase secretion, based on many clinical observations, causing a much 
lower 𝜙𝐷/𝜙𝑃 ratio than a healthy participant with a high first phase insulin secretion. Result 
in Chapter 8 showed that as a participant diagnoses with IFG (G0 > 5.56 mmol·L
-1), the value 
of 𝜙𝐷 tends to reduce and becomes almost equal to 𝜙𝑃. However, for NGT participant (G0 < 
5.56 mmol·L-1), 𝜙𝐷 has a greater value than 𝜙𝑃. Thus, as the metabolic state of a participant 
moves from NGT to pre-diabetes state, the participant is losing burst secretion for first 
phase results in decrease in 𝜙𝐷. 
 
Overall, this thesis has thus delivered these main results to improve the mathematical and 
clinical precision of model-based tests to monitor and diagnosis T2D and its pathogenesis. 
These outcomes resulted in first of their kind models and observations. The methods 
created offer significant future potential as both diagnostic or monitoring, model-based 
biomarkers. 
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9.2  Future work 
 
The outcomes presented in this thesis provide good ground breaking findings in 
understanding the pathogenesis of type 2 diabetes particularly in insulin sensitivity and 
secretion. However, further optimisation can be implemented to improve the early 
diagnosis capability on pre-diabetes stage. 
 
9.2.1  The role of basal glucose (GB) 
 
Chapter 3, 4 and 5 elucidate the importance of defining the role of GB when assessing the SI 
value particularly in individuals with established type 2 diabetes. Result shows that when GB 
is not an identified variable, the participants’ glycaemic dynamics are potentially wrongly 
attributed to SI, and that identification of GB provides a more clinically representative result. 
However, more validation on different cohort, healthy and hyperglycemia, as well as 
different model-based SI assessment approach is required to confirm this outcome. 
 
As GB ≠ G0, it is suggested that the need to fast overnight before undertaking the clinical trial 
is reviewed. The definition of G0 = GB is already argued as study shows that walking in the 
morning or coming up to the clinic while fasting have G0 slightly higher than overnight GB 
levels (Holman & Turner 1981). Thus, while suggesting the participant or volunteer to 
monitor their food consumption, a much relax environment would potentially provide 
better assessment on the SI value. 
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9.2.2  Endogenous insulin secretion model (UN) 
 
Although the main focus of developing this PD UN model is to eliminate the use of C-peptide 
measurements, there is a need for a thorough validation for accuracy for this proposed 
model. Theoretically, UN is based on three physiological responses: UB is the basal 
endogenous production rate; U1, the magnitude of the first phase response to glucose 
appearance; and U2 is the second phase response to glucose (Cheng et al. 2013; Docherty 
2011). However, UB is still dependent on C-peptide measurement at steady state. 
 
Additionally, the interpretation of PD gains of 𝜙𝐷 and 𝜙𝑃 provides a direct relationship 
between UN profile and the metabolic state of participant. However, characterising the 𝜙𝐷 
and 𝜙𝑃 as a function of participants’ anatomical characteristic (weight, height, age, sex) 
would provide better estimation of UN profile. Further validation with larger and different 
cohort is required to quantify the accuracy of this PD UN model. 
 
9.2.3 Real time assessment of insulin sensitivity and secretion 
 
The real time aspect refers to neglecting the use of insulin and C-peptide measurements 
during parameter identification. With the use only of glucose measurements, a diagnostic 
outcome can be generated within few minutes of test completion. Thus, it could 
immediately provide an outcome that can be used by the researcher/ clinician to further 
understand and better control of the participant’s health condition.  
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